WO2021167011A1 - 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ - Google Patents
検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ Download PDFInfo
- Publication number
- WO2021167011A1 WO2021167011A1 PCT/JP2021/006153 JP2021006153W WO2021167011A1 WO 2021167011 A1 WO2021167011 A1 WO 2021167011A1 JP 2021006153 W JP2021006153 W JP 2021006153W WO 2021167011 A1 WO2021167011 A1 WO 2021167011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- sample
- acid sequence
- seq
- lactate dehydrogenase
- Prior art date
Links
- 108700023483 L-lactate dehydrogenases Proteins 0.000 title claims abstract description 180
- 102000003855 L-lactate dehydrogenase Human genes 0.000 title claims abstract description 179
- 238000000034 method Methods 0.000 title claims abstract description 165
- 230000009471 action Effects 0.000 claims abstract description 43
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 210000003722 extracellular fluid Anatomy 0.000 claims abstract description 7
- 210000003296 saliva Anatomy 0.000 claims abstract description 5
- 210000001138 tear Anatomy 0.000 claims abstract description 5
- 210000002700 urine Anatomy 0.000 claims abstract description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 268
- 150000001413 amino acids Chemical class 0.000 claims description 172
- 239000004310 lactic acid Substances 0.000 claims description 134
- 235000014655 lactic acid Nutrition 0.000 claims description 134
- 238000012545 processing Methods 0.000 claims description 130
- 230000008569 process Effects 0.000 claims description 99
- 238000005259 measurement Methods 0.000 claims description 63
- 238000012544 monitoring process Methods 0.000 claims description 35
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 33
- 230000001419 dependent effect Effects 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- -1 interstitial fluid Substances 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 239000002689 soil Substances 0.000 claims description 20
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 19
- 230000000977 initiatory effect Effects 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 210000003491 skin Anatomy 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 210000004243 sweat Anatomy 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000005070 ripening Effects 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000005252 bulbus oculi Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000004190 Enzymes Human genes 0.000 abstract description 61
- 108090000790 Enzymes Proteins 0.000 abstract description 61
- 238000011156 evaluation Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 83
- 239000000523 sample Substances 0.000 description 76
- 239000000243 solution Substances 0.000 description 62
- 229940088598 enzyme Drugs 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 59
- 229940024606 amino acid Drugs 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 52
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 38
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 238000003860 storage Methods 0.000 description 29
- 241000251468 Actinopterygii Species 0.000 description 28
- 235000015278 beef Nutrition 0.000 description 26
- 241000283690 Bos taurus Species 0.000 description 25
- 241000196324 Embryophyta Species 0.000 description 24
- 239000008057 potassium phosphate buffer Substances 0.000 description 24
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 241000777300 Congiopodidae Species 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000036541 health Effects 0.000 description 15
- 235000013372 meat Nutrition 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- 239000000370 acceptor Substances 0.000 description 9
- 235000013365 dairy product Nutrition 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000011768 flavin mononucleotide Substances 0.000 description 8
- 229940013640 flavin mononucleotide Drugs 0.000 description 8
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 8
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 102000004316 Oxidoreductases Human genes 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- 229910021607 Silver chloride Inorganic materials 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000010365 information processing Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000672609 Escherichia coli BL21 Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229910021397 glassy carbon Inorganic materials 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- BAWFJGJZGIEFAR-DQQFMEOOSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-DQQFMEOOSA-N 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000010411 cooking Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 101150104734 ldh gene Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003501 hydroponics Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000014101 wine Nutrition 0.000 description 3
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 2
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
- 108010074122 Ferredoxins Proteins 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000641031 Homo sapiens Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Chemical group 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000276 potassium ferrocyanide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006076 specific stabilizer Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 2
- AWDBHOZBRXWRKS-UHFFFAOYSA-N tetrapotassium;iron(6+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] AWDBHOZBRXWRKS-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 235000015041 whisky Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NHQAUSOKYWFWHO-UHFFFAOYSA-N 4-aminobutane-2-sulfonic acid Chemical compound OS(=O)(=O)C(C)CCN NHQAUSOKYWFWHO-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 241000221955 Chaetomium Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 102000000428 Lactate Dehydrogenases Human genes 0.000 description 1
- 108010080864 Lactate Dehydrogenases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001444203 Madurella mycetomatis Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001112159 Ogataea Species 0.000 description 1
- 241001099341 Ogataea polymorpha Species 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001238980 Thermothelomyces Species 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000012791 bagels Nutrition 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical class Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000007646 gravure printing Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 108010088076 lactate dehydrogenase 2 Proteins 0.000 description 1
- 108010088074 lactate dehydrogenase 3 Proteins 0.000 description 1
- 108010088351 lactate dehydrogenase 4 Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001791 phenazinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical class C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 150000004986 phenylenediamines Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q3/00—Condition responsive control processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/05—Oxidoreductases acting on the CH-OH group of donors (1.1) with a quinone or similar compound as acceptor (1.1.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2520/00—Reactions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Definitions
- the present invention uses a device for evaluating the condition of a sample, including a sensor using a flavin-dependent lactate dehydrogenase using a flavin compound as a coenzyme, a system in which the device further includes an output unit, the device or the system.
- the present invention relates to a method for evaluating the condition of a sample.
- the present invention also relates to flavin-dependent lactate dehydrogenase which can be suitably used for the devices, systems and methods for evaluating the state of a sample using them.
- Blood lactate concentration and sweat lactate concentration are known as markers that reflect fatigue and physical condition. Lactic acid is a major metabolite and is recognized to be important not only for health care indicators but also for health assessments involving serious illness and / or surgical patients, and lactic acid levels in body fluids are circulatory insufficiency, liver. It can be an index for various pathological conditions such as disorders. Lactate monitoring can be used to detect sepsis, hypoxia, and the presence of cancerous tissue (Non-Patent Document 1).
- Lactate monitoring is also used as an index for monitoring the appropriateness of training conducted by athletes and those who are highly interested in exercising on a daily basis, not only for the purpose of physical condition management for sick people. (Non-Patent Document 2).
- Patent Documents 1 to 3 propose predetermined information processing devices as technical proposals for continuously monitoring a human condition, posture, etc. for a certain period of time (Patent Documents 1 to 3).
- Lactic acid oxidase (hereinafter, LOD) is known as an enzyme using lactic acid as a substrate. LOD has a problem that its activity is lost during storage after drying. Therefore, Patent Document 4 proposes a method of drying in combination with a specific stabilizer in the drying step.
- Patent Document 5 also proposes a lactic acid sensor in which catalase coexists for the purpose of eliminating hydrogen peroxide as a means for avoiding a decrease in LOD activity due to hydrogen peroxide.
- FMN-LDH FMN-dependent lactate dehydrogenase
- JP-A-2019-150649 Japanese Unexamined Patent Publication No. 2017-100039 International Publication No. 17/163521 Pamphlet Patent No. 5593689 Special Table 2018-519507
- the lactic acid level in food can be an index for quality control, etc.
- Good quality at the production site of various fermented foods and drinks produced through the lactic acid fermentation process such as sake, wine, whiskey, cheese, yogurt, sauerkraut, waste rice cake, pickles, miso, soy sauce, and lactic acid fermented yeast extract.
- appropriate lactic acid fermentation process control is performed, and in the process control, the amount of lactic acid can be an index of production process control.
- lactic acid is not limited to foods and drinks fermented with lactic acid, but also in, for example, a lactic acid fermentation composition obtained by fermenting a plant material which is a raw material for cosmetics with lactic acid bacteria, and a lactic acid composition produced as a chemical product. It is progressing, and the amount of lactic acid can be an index in the manufacturing process control and quality control of such products.
- the amount of lactic acid in the monomer can be used as an index when calculating the decomposition rate.
- the measurement of the amount of lactic acid performed for the above purpose can be carried out frequently and easily in daily life or in the manufacturing process of foods and drinks every time, and more preferably it can be repeated in the simplest possible process. It is even more preferable to be able to monitor automatically and continuously.
- the infiltration sampling method such as puncture in the current measurement method causes pain and stress for the biological sample, and hinders frequent sampling. Also, in the manufacturing process control of foods and drinks that do not have the problem of pain and stress, lactic acid is manually sampled from the lactic acid-containing composition being manufactured each time, and then the lactic acid is measured and the measurement data is manually recorded each time. Such frequent sampling operations in current lactate measurement techniques are cumbersome because they must be.
- a technical proposal for continuously monitoring the human condition and posture for a certain period of time for example, a plurality of sensors are attached to the human body, clothing, training machine, etc., and some biological origin obtained by these sensors is obtained.
- a system for proposing training programs based on data and input information such as the age and gender of the person, estimating the physical condition of the person, an information processing device for activating an application program based on various data, etc. It has been proposed (Patent Documents 1 to 3). And, in a small number of such proposals, some include the word lactate measurement. However, in those proposals, no method is disclosed that can specifically measure the amount of lactic acid as an actual index and thereby monitor the state of the sample.
- Patent Document 1 it can be attached to a training device for riding a bicycle, and heart rate information acquired from a human (driver) during training time by a heart rate monitor can be obtained as a resting heart rate of the driver or a heart rate during training.
- a system has been proposed that can analyze based on information such as age and gender and bicycle running data, and output a message for bringing the current exercise state of the driver closer to the ideal state.
- the blood flow in each of the first part where the blood flow does not fluctuate according to the physical condition of a human and the second part where the blood flow fluctuates according to the physical condition is measured by a laser speckle camera, a laser Doppler blood flow system, etc.
- a system for estimating such factors has been proposed.
- human body temperature, acceleration, heart rate data, GPS data, altitude data, etc. are used by using one or more wearable sensors attached to human underwear or jacket, hat or glasses, earplugs, headphones, or the like.
- An information processing device that can monitor the posture of the person wearing these, estimate the movements such as sleeping, waking up, walking, etc., and if there is a sign of altitude sickness during mountain climbing, etc. has been proposed.
- Examples of enzymes using lactic acid as a substrate include lactate oxidase (hereinafter, LOD), NAD-dependent lactate dehydrogenase (hereinafter, NAD-LDH) using nicotinamide dinucleotide (NAD) as a coenzyme, and flavin mononucleotide (FMN). ) Is a coenzyme, and FMN-dependent lactate dehydrogenase (hereinafter, FMN-LDH) is known.
- LOD lactate oxidase
- NAD-LDH NAD-dependent lactate dehydrogenase
- NAD-LDH nicotinamide dinucleotide
- FMN flavin mononucleotide
- FMN-LDH FMN-dependent lactate dehydrogenase
- Blood lactic acid measuring devices using LOD are commercially available, and each time a measurement is performed, the stored sensor (the electrode part for measuring blood lactic acid including LOD) is taken out
- the blood squeezed from the sample is sucked into the sensor, and the measured value displayed on the measuring device is read.
- the amount of lactic acid in the sample can be known in a single-shot manner, and by repeating this, the amount of lactic acid in the sample can be measured each time.
- lactic acid in the lactic acid-containing composition containing biological interstitial fluid, blood and sweat, food and drink and chemical products is measured stably, accurately and preferably continuously and easily over a long period of time. If you want to do this, known measurement enzymes are not sufficient.
- LOD has a problem of insufficient thermal stability, and even when manufacturing a LOD product, the degree of activity being lost during the drying process or storage after drying is large.
- Patent Document 4 a method of drying in combination with a specific stabilizer in the drying step has also been proposed (Patent Document 4), but the effect of improving the stability is still insufficient. It should also be considered that the stability of LOD in the liquid state during the actual enzymatic reaction is even lower than the stability in the powder state.
- lactic acid is monitored for a long period of time in a scene where a sensor using LOD is used in close contact with the human body for a long period of time, or in a manufacturing process of foods and drinks that can be placed at a fermentation temperature in a lactic acid bacteria fermentation process.
- a sensor using LOD is used in close contact with the human body for a long period of time, or in a manufacturing process of foods and drinks that can be placed at a fermentation temperature in a lactic acid bacteria fermentation process.
- the existing LOD cannot exhibit sufficient practicality from the viewpoint of enzyme stability from around room temperature to around 37 ° C., which is near human body temperature.
- LOD also has a problem of producing hydrogen peroxide as a reaction product.
- hydrogen peroxide which is one of the active oxygen species and the causative agent of oxidative stress.
- hydrogen peroxide generated by the action of LOD also has an adverse effect on the stabilization of LOD itself, and as a means for avoiding a decrease in LOD activity due to this, a lactic acid sensor in which catalase coexists for the purpose of eliminating hydrogen peroxide has also been proposed. (Patent Document 5).
- NAD-LDH catalyzes an enzymatic reaction that does not generate hydrogen peroxide
- the problem of hydrogen peroxide production does not occur.
- lactic acid and pyruvic acid react reversibly, there is a problem that an accurate measured value cannot be obtained for the use of quantification, and the sensor. It is difficult to adopt for.
- FMN-LDH also catalyzes an enzymatic reaction that does not produce hydrogen peroxide, so the problem of hydrogen peroxide production does not arise.
- FMN-LDH derived from Saccharomyces cerevisiae known so far. Then, there is still a problem in stability (Non-Patent Document 3).
- An object of the present invention is to provide a device for monitoring or evaluating the state of a sample, a method for monitoring or evaluating the state of a sample, and an FMN-LDH used therefor, which can solve at least a part of the above problems. And.
- the present inventor has conceived a device for evaluating the state of a sample having a configuration capable of easily measuring lactic acid in a sample non-invasively when measuring the amount of lactic acid in the sample. Then, a method for evaluating the state of a sample using such a device, a system used for the method, and an FMN-LDH suitable for measuring lactate were found, and the present invention was completed. Twice
- the present invention includes the following aspects.
- a device for evaluating the condition of a sample The action part for allowing lactate dehydrogenase to act on the sample, A device including a sensor for detecting the state of a sample on which lactate dehydrogenase has been acted, and a sensor arranged so as to be able to detect the state of the sample at the action site.
- the device according to (1) further including an output unit for outputting a signal from a sensor.
- the device described and A system that is connected to the output of a device and includes a data processing unit for processing signals from sensors.
- the device is The action part for allowing lactate dehydrogenase to act on the sample, A sensor for detecting the state of a sample on which lactate dehydrogenase has acted, and a sensor arranged so as to be able to detect the state of the sample at the action site. Includes an output section for outputting signals from the sensor A data processing unit is connected to the output of the device and is configured to process the signal from the sensor.
- the program tells the device A measurement process for detecting and measuring the state of a sample on which lactate dehydrogenase is applied at the action site and converting it into a signal, A transfer process for transferring the signal obtained in the measurement process from the output unit to the data processing unit is executed.
- (5) A method for evaluating the condition of a sample using the device according to (1) or (2) or the system according to (3).
- Lactic acid containing human and non-human organisms such as body fluids, interstitial fluid, blood, urine, tears, sweat, saliva, skin, flesh, eyeballs, cornea, gastric fluid, food and drink, brews, chemicals, water, and soil.
- the method according to (5) which is a containing composition.
- the condition of the sample is physical condition with respect to exercise load, disease condition, brewing condition of brewed product with change of lactic acid amount, aging / ripening degree of food and drink with change of lactic acid amount, chemical product manufacturing with change of lactic acid amount.
- the method according to (5) or (6) which is the lactic acid content ratio of lactic acid, the amount of lactic acid in water or soil accompanied by a change in the amount of lactic acid.
- a device for monitoring the condition of a sample which is a device for the sample.
- Flavin-dependent lactate dehydrogenase which maintains about 20% or more of its initial activity when allowed to pass at 37 ° C. for 10 days in solution.
- Flavin-dependent lactate dehydrogenase that maintains about 20% or more of the initial activity when allowed to pass at 37 ° C. for 3 days or more in the solution (B), or 15 at 37 ° C. in the solution (C).
- a device comprising an action part for acting flavin-dependent lactate dehydrogenase, which maintains about 20% or more of the initial activity when the time has passed.
- amino acid sequence at positions 110 to 502 in the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence having 70% or more identity with it the amino acid sequence at positions 113 to 505 in the amino acid sequence shown in SEQ ID NO: 7 or 70% or more thereof.
- a lactate dehydrogenase comprising the amino acid sequence at positions 102 to 499 in the sequence or the amino acid sequence represented by SEQ ID NO: 12 or an amino acid sequence having 70% or more identity with the amino acid sequence.
- (14) (13) A host cell having the nucleic acid described.
- (15) (14) A method for producing lactate dehydrogenase, which comprises culturing the host cell according to the above.
- (16) A method for evaluating the condition of a sample A method comprising i) contacting a sample with lactate dehydrogenase according to (11) or (12), and ii) measuring lactate.
- FIG. 1A is a schematic view of a sensor chip 10 according to an embodiment of the present invention
- FIGS. 1B to 1D are schematic views showing members constituting the sensor chip 10.
- FIG. 2 is a diagram showing the residual activity rates of PkLDH and ScLDH after heat treatment at each temperature.
- 3A and 3B are diagrams showing the residual activity rates of PkLDH, ScLDH, CalDH and OgLDH after storage at 37 ° C. for each time.
- FIG. 4 is a schematic diagram showing an example of a device and a system according to an embodiment of the present invention.
- FIG. 5 is a flow chart showing an example of the program according to the embodiment of the present invention.
- FIG. 6 is a schematic view showing an example of a device and a system using the transmitter according to the embodiment of the present invention.
- FIG. 7 is a diagram showing the stable pH of PkLDH evaluated in Example 4.
- FIG. 8 is a diagram showing the optimum pH of PkLDH evaluated in Example 4.
- FIG. 9 is a diagram showing the relationship between the lactic acid concentration evaluated in Example 4 and the activity of PkLDH.
- FIG. 10 is a diagram showing the relationship between the lactic acid concentration evaluated in Example 8 and the response current value.
- FIG. 11-1 shows the alignment of the amino acid sequences of the lactate dehydrogenase of the present invention.
- FIG. 11-2 is a continuation of FIG. 11-1.
- FIG. 11-1 shows the alignment of the amino acid sequences of the lactate dehydrogenase of the present invention.
- FIG. 11-2 is a continuation of FIG. 11-1.
- FIG. 11-1 shows the alignment of the amino acid sequences of the lactate dehydrogenase of the
- FIG. 12 is a diagram showing the residual activity rates of PkLDH and N-terminal deleted mutants of PkLDH treated at 55 ° C. for 15 minutes evaluated in Example 11.
- FIG. 13 is a diagram showing the residual activity rates of PkLDH and monosubstituted mutants treated in Example 11 at 55 ° C. for 15 minutes.
- the sample referred to in the present invention may be a target for measuring whether or not it contains lactic acid, and is a body fluid of human and non-human organisms such as interstitial fluid, blood, urine, tears, sweat, saliva, skin, and meat. , Eyeball, corneal membrane, gastric fluid, or a lactic acid-containing composition containing non-lactic acid-fermented, lactic-fermented or lactic-fermented foods and drinks, brewed products, and chemical products. Furthermore, it may be present in an environment such as water containing lactic acid or soil.
- the lactate dehydrogenase (LDH) referred to in the present invention may be an enzyme that catalyzes a reversible reaction of reducing pyruvate ions to lactate ions using NADH, which is a reducing agent, and may be NAD-dependent lactate dehydrogenase and FMN-dependent lactate.
- Dehydrogenase is known, but preferably FMN-dependent lactate dehydrogenase, more preferably the amino acid sequence represented by SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, or SEQ ID NO: 12 or 70% or more, 75% or more, 80 thereof.
- Amino acid sequences at positions 1 to 88 in SEQ ID NO: 12, or amino acid sequences having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more identity with them are linked. You can also do it.
- Amino acid sequence of, amino acid sequence of positions 1 to 99 in SEQ ID NO: 7, amino acid sequence of positions 1 to 98 in SEQ ID NO: 10, amino acid sequence of positions 1 to 88 in SEQ ID NO: 12 or 70% or more, 75% or more with them, Amino acid sequences having 80% or more, 85% or more, 90% or more, or 95% or more identity can also be linked.
- the region containing the region has low sequence identity and can be said to be of low importance in the lactate dehydrogenase of the present invention. Therefore, among the full-length amino acid sequences, the amino acid sequence at positions 97 to 502 in SEQ ID NO: 4, the amino acid sequence at positions 100 to 505 in SEQ ID NO: 7, the amino acid sequence at positions 99 to 503 in SEQ ID NO: 10, and 89 in SEQ ID NO: 12.
- lactate dehydrogenase containing an amino acid sequence at position ⁇ 499 or an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more identity with the amino acid sequence.
- the amino acid sequence of positions 1 to 96 in No. 4 the amino acid sequence of positions 1 to 99 in SEQ ID NO: 7, the amino acid sequence of positions 1 to 98 in SEQ ID NO: 10, or the amino acid sequence of positions 1 to 88 in SEQ ID NO: 12.
- the sequence identity may be 45% or more, 50% or more, 60% or 70% or more, respectively, or this region may be deleted.
- amino acids may be deleted from the N-terminal sequence. ..
- amino acids at positions 2 to 10 in SEQ ID NO: 4 may be deleted. If deleted, methionine can be added at the beginning of the sequence, as appropriate.
- Amino acid sequence identities or similarities can be found in GENETYX Ver. It can be calculated by a program such as maximum matching or search homology of 11 (manufactured by Genetics) or a program of maximum matching or multiple alignment of DNASIS Pro (manufactured by Hitachi Solutions).
- the amino acid sequence identity when two or more LDHs are aligned, the positions of amino acids that are the same in the two or more LDHs can be examined. Based on this information, the same region in the amino acid sequence can be determined. It is also possible to investigate the positions of amino acids that are similar in two or more LDHs. For example, CLUSTALW can be used to align a plurality of amino acid sequences.
- Blossum62 is used as an algorithm, and amino acids judged to be similar when a plurality of amino acid sequences are aligned may be referred to as similar amino acids.
- amino acid substitutions can be due to substitutions between such similar amino acids.
- the amino acid sequence in the homology region of lactate dehydrogenase of the present invention is 75% or more, for example, 80% or more, 81% or more, 82% or more, 83% or more, 84% with the amino acid sequence of the homology region in SEQ ID NO: 4.
- the device for evaluating the state of the sample in the present invention includes an action part for causing lactate dehydrogenase to act on the sample, and a sensor for detecting the state of the sample on which lactate dehydrogenase is allowed to act.
- the sensor is arranged so that it can sense the state of the sample at the action site.
- the working part of the sensor may be included by a gel, preferably a biocompatible gel.
- the lactic acid in the sample can be detected by bringing the gel into contact with the sample, collecting water containing lactic acid through the gel by the effect of osmotic pressure or the like, and contacting the sensor with lactic acid.
- the biocompatible component (that is, the material of the gel constituting the gel structure) is particularly limited as long as it has cell adhesion, biocompatibility, high transparency, and hydrophilicity.
- synthetic molecules and biomolecules can be used.
- the synthetic molecule described above include hydrophilic acrylic molecules such as polyethylene glycol and acrylamide.
- polyethylene glycol dimethacrylate is a stretchable polymer, and is preferable because it can improve not only affinity for cells and biological tissues but also stretchability, viscoelasticity, and toughness.
- biomolecules include polysaccharides such as sodium alginate, protein materials such as gelatin and silk, and extracellular matrix such as collagen. Among these, a material containing a large amount of protein is preferable.
- the biocompatible gel material of the present embodiment it is preferable to use silk fibroin gel as one of the components having biocompatibility.
- a silk fibroin gel containing a large amount of protein By using a silk fibroin gel containing a large amount of protein, cytotoxicity can be reduced so that the surface of the gel material is highly biocompatible and the promotion of cell adhesion is observed.
- the synthetic molecule and biomolecule described above may be a polymer or a small molecule.
- the molecular weight (Mw) of the polymer is not particularly limited as long as the polymer can form a gel structure, and for example, a polymer having a molecular weight of about 5,000 to 1,000,000 Da is used. Can be done.
- the action part for acting lactate dehydrogenase is a member that acts on an enzyme made of a material such as metal, plastic, cloth, liquid, paper, or nylon, as long as it is made of a material suitable for the action.
- the sensor that senses the state of the sample may be integrated with a member on which the enzyme acts, may be separated from the sensor, or may be directly or indirectly connected.
- a sample and the lactate dehydrogenase of the present invention are placed in the action section.
- an electron acceptor and / or a reagent for showing a change in the electron acceptor (mediator) can be arranged in the action part.
- a sensor that includes a working part (sometimes referred to as a working electrode) has a working electrode, a reference electrode, and a counter electrode that include the LDH of the present invention.
- a working electrode a carbon electrode, a gold electrode, a platinum electrode, or the like is used, and the LDH of the present invention is immobilized on the electrode. Further, or separately, an electron mediator may be immobilized on the working electrode.
- the counter electrode can be a platinum electrode, a conventional electrode such as Pt / C, or the like.
- the reference electrode can be a conventional electrode such as an Ag / AgCl electrode.
- Immobilization methods include a method using a cross-linking reagent, a method of encapsulating in a polymer matrix, a method of coating with a dialysis membrane, a photocrosslinkable polymer, a conductive polymer, an oxidation-reduced polymer, etc., or a ferrocene or a derivative thereof. It may be fixed in a polymer or adsorbed and fixed on an electrode together with a representative electronic mediator, or these may be used in combination.
- the LDH of the present invention is immobilized on a carbon electrode with glutaraldehyde and then treated with a reagent having an amine group to block glutaraldehyde.
- Cross-linking reagents such as poly (ethylene glycol) diglycidyl ether can also be used instead of glutaraldehyde.
- the sensor that can be used in the device of the present invention can be used without limitation as long as it can detect the state of the sample on which lactate dehydrogenase is acted.
- a sensor chip may be used as the sensor.
- 1 (a) is a schematic view of a sensor chip 10 according to an embodiment of the present invention
- FIGS. 1 (b) to 1 (d) are schematic views showing members constituting the sensor chip 10.
- the sensor chip 10 includes two or more electrodes arranged on the base material 11.
- the base material 11 is made of an insulating material.
- the working electrode 1, the counter electrode 3 and the reference electrode 5 are arranged on the base material 11.
- Each electrode is electrically connected to the wiring portion 7, and the wiring portion 7 is electrically connected to a terminal 9 located on the opposite side of the wiring direction from each electrode.
- the working pole 1, the counter electrode 3 and the reference pole 5 are arranged apart from each other. Further, it is preferable that the working electrode 1, the counter electrode 3 and the reference electrode 5 are integrally formed with the wiring portion 7 and the terminal 9. Further, the counter electrode 3 and the reference electrode 5 may be integrated.
- a spacer 13 is arranged at the end of the base material 11 parallel to the wiring portion 7, and the working electrode 1, the counter electrode 3, the reference electrode 5 and the spacer 13 are arranged.
- a cover 15 for covering the above is arranged.
- the spacer 13 and the cover 15 are made of an insulating material. It is preferable that the spacer 13 has a thickness substantially equal to that of the working pole 1, the counter electrode 3 and the reference pole 5, and is in close contact with the working pole 1, the counter electrode 3 and the reference pole 5. Further, the spacer 13 and the cover 15 may be integrally formed.
- the cover 15 is a protective layer that prevents the wiring portion 7 from being deteriorated by being exposed to the outside air and short-circuiting due to the penetration of the measurement sample.
- the reaction layer 19 is arranged on the working electrode 1, the counter electrode 3 and the reference electrode 5.
- the reaction layer 19 provides a field for the reaction of lactic acid with lactate dehydrogenase.
- the lactate dehydrogenase of the present invention may be applied, adsorbed, or immobilized on these electrodes.
- the lactate dehydrogenase of the present invention is applied, adsorbed or immobilized on the working electrode.
- the mediator as well as lactate dehydrogenase may be applied, adsorbed, or immobilized on the electrode.
- a carbon electrode, a metal electrode such as platinum, gold, silver, nickel and palladium can be used.
- examples of the material include pyrolytic graphite carbon (PG), glassy carbon (GC), carbon paste and plastic foamed carbon (PFC).
- the measurement system may be a two-electrode system or a three-electrode system, for example, the enzyme can be immobilized on the working electrode.
- examples of the reference electrode include a standard hydrogen electrode, a reversible hydrogen electrode, a silver-silver chloride electrode (Ag / AgCl), a palladium / hydrogen electrode, a saturated calomel electrode, and the like. From the viewpoint of stability and reproducibility, Ag / AgCl is used. It is preferable to use it.
- a printed electrode can be used to reduce the amount of solution required for measurement.
- the electrodes are preferably formed on the base material 11 made of an insulating substrate. Specifically, it is desirable that electrodes are formed on the base material 11 by a photolithography technique or a printing technique such as screen printing, gravure printing, or flexographic printing. Examples of the material of the insulating substrate include silicon, glass, ceramic, polyvinyl chloride, polyethylene, polypropylene and polyester, but it is more preferable to use a material having strong resistance to various solvents and chemicals.
- potassium ferricyanide when lactate dehydrogenase is allowed to act on lactic acid contained in a sample in an action part containing potassium ferricyanide as an electron acceptor, potassium ferricyanide changes to potassium ferrocyanide. Since potassium ferricyanide absorbs at a wavelength of 420 nm, the state of lactic acid in the sample can be sensed by measuring the absorbance at a wavelength of 420 nm with a spectrophotometer. It is also possible to electrochemically measure the redox reaction when lactate dehydrogenase is allowed to act on lactic acid and potassium ferricyanide is allowed to act on the lactic acid.
- a sensor for performing an electrochemical measurement for example, a sensor of Arkray's Lactate Pro 2 model number LT-1730 can be used.
- Other electron acceptors include quinones, phenazines (eg, phenazinemethsulfate), viologens, cytochromes (eg, cytochrome b, cytochrome c), phenoxazines, phenothiazines, ferricianides, ferredoxins, etc.
- Ferredoxin, osmium complex, ruthenium complex, phenylene diamines and derivatives thereof and the like can be used.
- the lactate dehydrogenase of the present invention does not use oxygen as an electron acceptor.
- the lactic acid concentration can be measured as follows. Put the buffer solution in the constant temperature cell and keep it at a constant temperature.
- As the working electrode an electrode on which LDH and an electron acceptor (for example, a quinone-added polymer) are immobilized is used, and a counter electrode (for example, a platinum electrode) and a reference electrode (for example, an Ag / AgCl electrode) are used.
- a constant voltage is applied to the carbon electrode, and after the current becomes steady, a sample containing L-lactic acid is added and the increase in the current is measured.
- the lactic acid concentration in the sample can be calculated according to the calibration curve prepared with the standard concentration lactic acid solution.
- the 4U LDH of the present invention is immobilized on a glassy carbon (GC) electrode, and the response current value with respect to the lactic acid concentration is measured.
- a glassy carbon (GC) electrode To the electrolytic cell, 1.8 ml of 50 mM potassium phosphate buffer (pH 7.5) and 0.2 ml of a 1 M potassium hexacyanoferrate (III) aqueous solution (potassium ferricyanide) are added.
- a GC electrode is connected to a potentiostat BAS100B / W (manufactured by BAS), the solution is agitated at 37 ° C., and +500 mV is applied to the silver-silver chloride (saturated KCl) reference electrode.
- a 1 M L-lactic acid solution is added to these systems so that the final concentration is 1, 2, 3, 4, 5, 10, 20, 30, 40, 50 mM, and the steady-state current value is measured for each addition.
- This current value is plotted against known lactate concentrations (1, 2, 3, 4, 5, 10, 20, 30, 40, 50 mM) to create a calibration curve. This makes it possible to quantify lactic acid using an enzyme-immobilized electrode using the FMN-LDH of the present invention.
- the lactic acid sensor chip of the present invention has 0.01U to 1000U, 0.1U to 1000U, more preferably 0.5U to 700U, more preferably 0.5U to 500U, more preferably 1U to the present invention.
- a 300 U, more preferably 1 U to 100 U FMN-LDH solution is applied or immobilized.
- a continuous lactate monitoring device having the lactate sensor of the present invention is provided. Also, in certain embodiments, a method of continuously monitoring lactic acid for 14 days using the LDH of the present invention is provided. The measurement period is 5 seconds, 1 minute, 5 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 15 hours, 24 hours, 2 days, 5 days, 7 days, 10 days, 14 days, etc. Can be set together.
- continuous lactate monitoring can be performed with or without recalibration.
- recalibration can be performed every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days.
- the lactate dehydrogenase of the present invention has sufficient thermal stability. Therefore, simple and preferably continuous lactate monitoring can be realized.
- the present invention also relates to a method for measuring lactate, which comprises i) contacting a sample with lactate dehydrogenase and ii) measuring lactate.
- the lactate dehydrogenase in step i) is an FMN-dependent lactate dehydrogenase, more preferably the amino acid sequence represented by SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, or SEQ ID NO: 12 or 70% or more, 75% thereof.
- lactate dehydrogenase having an amino acid sequence having 80% or more, 85% or more, 90% or more, or 95% or more identity.
- the lactate dehydrogenase in step i) is 0.01U to 1000U, 0.1U to 1000U, more preferably 0.5U to 700U, more preferably 0.5U to 500U, and more preferably 1U to 300U. , More preferably 1U-100U lactate dehydrogenase. Further, the lactate dehydrogenase of step i) has an initial activity of about 20% or more, 30% or more, 40% or more when allowed to pass at about 30, 35 ° C. or 37 ° C. for 10 days in the solution (A).
- Flavin-dependent lactate dehydrogenase maintaining 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more; at about 30, 35 ° C or 37 ° C in the solution (B).
- the initial activity is maintained at about 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more.
- step i) 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more may be flavin-dependent lactate dehydrogenase.
- the temperature at which the lactate dehydrogenase in step i) is brought into contact with the sample may be 20 to 60 ° C, preferably 30 to 55 ° C, and preferably 30 to 40 ° C. It should be.
- the pH at the time of contacting the lactate dehydrogenase in step i) with the sample may be in the range of 3 to 10, preferably in the range of 5 to 9, preferably in the range of 6 to 8. All you need is.
- the step of measuring lactic acid in step ii) may be a single measurement or a continuous measurement.
- the measurement period of step ii) is 5 seconds, 1 minute, 5 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 15 hours, 24 hours, 2 days, 5 days, 7 days, 10 days or 14 days. But it may be.
- the device for evaluating the state of the sample in the present invention can further include an output unit.
- the output unit can output the signal from the sensor to the outside.
- the output unit may be connected to a data processing unit to form a system. That is, the system includes a device and a data processing unit.
- the data processing unit can process the signal from the sensor.
- the "data processing unit” not only means a device such as a single computer, but also performs information processing in the form of connecting other devices connected by a communication line such as a local network or the Internet. Includes the concept of networks for.
- connection between the output unit and the data processing unit means that the signal from the sensor is output from the output unit and connected by an electrical or electronic method so that it can be input to the data processing unit.
- a wireless communication such as a wireless LAN can also be used for connection.
- the data processing unit can include a control unit.
- the control unit can be, for example, a CPU (Central Processing Unit).
- the program described later can be read into the control unit.
- the data processing unit can include a storage unit.
- the "storage unit” refers to a memory, a hard disk, or the like that can write the input information so that it can be read.
- the storage unit can be arranged inside a predetermined device. Further, the storage unit can exist inside another device connected by a communication line such as a local network or the Internet. By including the storage unit, the signal measured by the sensor can be stored, and the result processed by the data processing unit can be stored.
- the data processing unit has a display unit for displaying the result processed by the data processing unit, can be connected to the display unit, or can be transferred to the display unit.
- a means for displaying a known display such as a display, a printing device, an audio output device, and output to the outside by a communication line such as a local network or the Internet can be used. That is, the display unit not only physically has the display device in the data processing unit, but also transfers the result to the other information processing device by transferring the data (result) to the other information processing device. Including displaying.
- the data processing unit can be equipped with a transmitter, and can be wirelessly transmitted and received to a separate measuring device equipped with a display unit and a storage unit.
- the transmitter measures the current value measured by the device with the measuring unit 100, and sends the current value to the control unit 101.
- the control unit 101 measures the temperature in the vicinity of the device by the temperature sensor 102, corrects the temperature, and then calculates the lactic acid concentration from the current value.
- the control unit 101 executes the calculation of the lactic acid concentration at predetermined sampling time intervals.
- control unit 101 performs integrated averaging of the calculated lactic acid concentration at predetermined recording time intervals and records it in the storage unit 103.
- the control unit 101 transmits the value stored in the storage unit 103 to the measuring device 106 via the communication unit 104 in response to an instruction from the measuring device 106.
- the transmitter in this embodiment has a built-in battery 105.
- the transmitter is configured to be discarded when the remaining battery level of the battery 105 becomes insufficient.
- the battery level of the battery 105 is monitored through the measuring device 106. Then, when the device is replaced, the measuring device 106 confirms whether or not the remaining battery 105 is sufficient for the next device replacement with respect to the remaining battery level of the transmitter battery 105. Then, if the remaining amount is insufficient, the user is instructed to replace the transmitter and the transmitter cannot be used.
- the state of the sample for example, the physical state with respect to exercise load, the disease state, the brewing state of the brewed product with a change in the amount of lactic acid, the degree of aging / ripening of foods and drinks with a change in the amount of lactic acid, It is possible to evaluate the lactic acid content ratio in the production of chemical products accompanied by changes in the amount of lactic acid, the condition of water and soil accompanied by changes in the amount of lactic acid, and the like.
- the lactate dehydrogenase used in the device of the present invention is about 20% or more, 30% or more, 40% or more of the initial activity when allowed to elapse at about 30, 35 ° C. or 37 ° C. for 10 days in the solution (A). , 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more flavin-dependent lactate dehydrogenase; in the solution (B), about 30, 35 ° C. or 37 ° C. About 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more of the initial activity when 3 days or more have passed.
- the above device may further include an output unit, and the output unit may be connected to a data processing unit to form a system.
- evaluation or monitoring can be performed non-invasively to the sample and can be measured directly without sampling steps, i.e. by inserting a test strip into the sensor. It is very advantageous in that it can be used for a long period of time with it stuck and inserted, instead of a disposable measurement like pressing a button.
- the program of the present invention is a program for evaluating the state of a sample by a system including a device and a data processing unit.
- the program can be application software that causes a predetermined information processing device to execute a predetermined process in order to operate a predetermined device.
- the program of the present invention can also be a mobile application (app).
- the program of the present invention is a program for operating the system as shown in FIG. 4 described above.
- the system includes devices and data processing units.
- the device includes an action unit, a sensor, and an output unit.
- the working unit, the sensor, and the output unit are as described above. That is, the action part is configured so that lactate dehydrogenase can act on the sample.
- the sensor is configured to be capable of sensing the state of the lactate dehydrogenase-treated specimen at the site of action.
- the output unit is configured to be able to output a signal from the sensor.
- the data processing unit is connected to the output section of the device and is configured to process the signal from the sensor.
- the data processing unit can include a control unit, a storage unit, and a display unit.
- the control unit, the storage unit, and the display unit are as described above.
- the program of the present invention causes the system to execute the measurement process S01, the transfer process S02, and the data process S03.
- the program of the present invention can further cause the system to execute the result display process S04.
- the program causes the system to execute a process so as to detect and measure the state of the sample on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- this program can be used as a program for the following purposes.
- the program of the present invention can be used as a program for food and beverage applications. Specifically, it is as follows.
- the program of this embodiment can be a program for managing the freshness of beef. That is, in this embodiment, the sample is beef.
- the program causes the system to execute a process so as to detect and measure the state of beef on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for making a data format suitable for controlling the freshness of beef.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for beef freshness management can be displayed on the display unit.
- the expiration date of beef can be predicted by monitoring the temperature and humidity in addition to the lactic acid level.
- the value of the meat can be calculated and used as an index of the selling price.
- the action part is directly attached to the beef, and the state of the meat can be sensed by a sensor.
- beef freshness management has been mainly controlled by temperature. Since the lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized. Therefore, according to the program of the present embodiment, freshness management using lactic acid as an index can be performed. Therefore, the transportation conditions and storage conditions of beef can be appropriately adjusted. By using the program of this embodiment, it can be used as an index that objectively shows the value of beef and can support the judgment of consumers.
- the program of this embodiment can be a program for the management and control index of beef aging. That is, in this embodiment, the sample is beef.
- the program causes the system to execute a process so as to detect and measure the state of beef on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for making a data format suitable for the management and control index of beef aging.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- the display can display data in a data format suitable for beef aging management and control indicators.
- the expiration date of beef can be predicted by monitoring the temperature, humidity, and pH in addition to the lactic acid level.
- the value of the meat can be calculated and used as an index of the selling price.
- the action part is directly attached to the beef, and the state of the meat can be sensed by a sensor.
- beef aging management has been mainly controlled by temperature. Since the lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized. Therefore, according to the program of the present embodiment, freshness management using lactic acid as an index can be performed. Therefore, the transportation conditions and storage conditions of beef can be appropriately adjusted. By using the program of this embodiment, it can be used as an index that objectively shows the value of beef and can support the judgment of consumers.
- the program of this embodiment can be a program for managing the freshness of fish such as tuna. That is, in the present embodiment, the sample is a fish such as tuna.
- the program causes the system to execute a process so as to detect and measure the state of fish such as tuna on which lactate dehydrogenase is acted on the action part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for making a data format suitable for managing the freshness of fish such as tuna.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for managing the freshness of fish such as tuna can be displayed on the display unit.
- the degree of freshness of fish such as tuna and the expiration date can be predicted by monitoring the temperature, humidity, and K value in addition to the lactic acid value.
- the value of the fish can be calculated and used as an index of the selling price.
- the action part can be directly attached to the eyes of the fish, and the state of the fish such as tuna can be detected by the sensor.
- the transportation conditions and storage conditions for fish such as tuna can be appropriately set.
- it can be used as an index that objectively shows the value of fish such as tuna, and can support the judgment of consumers and wholesalers.
- the program of the present embodiment can be a program for management and control index of ripening of fish such as tuna. That is, in the present embodiment, the sample is a fish such as tuna.
- the program causes the system to execute a process so as to detect and measure the state of fish such as tuna on which lactate dehydrogenase is acted on the action part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for making a data format suitable for the management and control index of ripening of fish such as tuna.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for the management and control index of ripening of fish such as tuna can be displayed on the display unit.
- the action part can be directly attached to the eyes of the fish, and the state of the fish such as tuna can be detected by the sensor.
- the aging management of fish such as tuna has been mainly controlled by the temperature, aging time, temperature of hot salt water to be thawed, and water temperature. Since the lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized. Therefore, according to the program of the present embodiment, aging management using lactic acid as an index can be performed. Therefore, the aging conditions for fish such as tuna can be appropriately set. By using the program of this embodiment, it can be used as an index that objectively shows the value of fish such as tuna, and can support the judgment of consumers and wholesalers.
- the program of this embodiment is a program for foods and beverages other than the above, for example, malolactic fermentation management of wine, fermentation management of bread such as sake and bagels, fermentation management of waste rice cake, lactic fermentation management of whiskey, and fermentation of tea. It can be a program for management, food safety indicators, etc. According to the program of this embodiment, fermentation management of brewed liquor such as wine and sake, which relies on experience and intuition, is appropriate by using pH value, dissolved oxygen value, etc. as indicators in addition to lactic acid value. It is possible to obtain various temperature control and fermentation period.
- the program of the present invention can be used as a program for animal use. Specifically, it is as follows.
- the program of this embodiment can be a program for managing racehorses. That is, in this embodiment, the sample is a racehorse.
- the program causes the system to execute a process so as to detect and measure the state of the racehorse on which lactate dehydrogenase is acted on the action part by the sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined process of the present embodiment is a process for converting the data format suitable for the management of racehorses.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for managing racehorses can be displayed on the display unit.
- a training program is set up using blood lactate as an index. It is known that the amount of lactic acid changes according to the intensity of exercise, and if the balance between the amount of oxygen demand and the amount of supply during exercise is maintained, blood lactic acid does not accumulate, and if the balance of supply and demand is lost, it increases. (From the JRA breeding ground diary, training load using lactic acid as an index). Therefore, in the present embodiment, the appropriateness of the training load of the racehorse can be evaluated. It is also possible to propose a horse training method using the obtained lactic acid level.
- the program of the present embodiment can perform training management and health management of racehorses.
- the horse is trained every time. It is also possible to reduce the burden on the trainer and the stress on the horse by collecting blood from the horse and measuring and analyzing it.
- the program of the present embodiment can be a program for measuring the degree of fatigue of a racehorse. That is, in this embodiment, the sample is a racehorse.
- the program causes the system to execute a process so as to detect and measure the state of the racehorse on which lactate dehydrogenase is acted on the action part by the sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined process of the present embodiment is a process for converting the data format suitable for measuring the fatigue level of a racehorse.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for measuring the degree of fatigue of a racehorse can be displayed on the display unit.
- the amount of lactic acid changes according to the degree of fatigue of the racehorse, so that the degree of fatigue of the racehorse can be predicted from the change in the amount of lactic acid.
- lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized. Therefore, since the program of the present embodiment can obtain an index indicating the muscle fatigue degree of the racehorse, even a beginner can judge the muscle fatigue degree of the racehorse.
- the program of the present embodiment can be a program for cattle health management, shipping judgment management, or beef cattle meat quality control. That is, in this embodiment, the sample is a cow.
- the program causes the system to execute a process so as to detect and measure the state of the cow on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for converting into a data format suitable for cattle health management, shipping judgment management, or beef cattle quality control.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for cattle health management, shipping time determination management, or beef cattle quality control can be displayed on the display unit.
- lactate dehydrogenase is allowed to act on the action part as an ear, and the state of the cow can be sensed and measured by a sensor.
- Blood vessels pass through the ear, and by arranging an action part and a sensor in the ear tag, it is possible to measure the blood of the ear as a specific sample. Sweat and skin can also be used as samples.
- the stomach it is also possible to use the stomach as an action part. For example, by measuring the amount of lactic acid in the blood, it is possible to suppress the administration of lactic acid bacteria or grains containing lactic acid before acute acidosis occurs.
- the swallowing sensor can be used for health management, shipping judgment management, or beef cattle quality control. That is, lactate dehydrogenase can be allowed to act on the action part as a digestive organ such as the stomach, and the state of cattle can be sensed and measured by a sensor.
- the amount of lactic acid assimilated by the microorganisms present in the stomach changes as a result according to the amount of lactic acid in the cow, and volatile fatty acids are generated according to the amount of lactic acid assimilated.
- lactate dehydrogenase of the present invention Since the lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized. Therefore, according to the program of the present embodiment, it is possible to manage the health of cattle, manage the determination at the time of shipment, or control the meat quality of beef cattle.
- the program of this embodiment can be a program for dairy cow health care. That is, in this embodiment, the sample is a dairy cow.
- the program causes the system to execute a process so as to detect and measure the state of the dairy cow on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined process of the present embodiment is a process for converting the data format suitable for the health management of dairy cows.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for dairy cow health management can be displayed on the display unit.
- lactate dehydrogenase is allowed to act on the action part as an ear, and the state of the dairy cow can be sensed and measured by a sensor.
- Blood vessels pass through the ear, and by arranging an action part and a sensor in the ear tag, it is possible to measure the blood of the ear as a specific sample. Sweat and skin can also be used as samples.
- the stomach it is also possible to use the stomach as an action part. For example, by measuring the amount of lactic acid in the blood, it is possible to suppress the administration of lactic acid bacteria or grains containing lactic acid before acute acidosis occurs.
- the program of this embodiment can manage the health of dairy cows.
- the value of the obtained dairy products can be evaluated from the viewpoint of the health condition of the final product and dairy cows, supporting the judgment of consumers and wholesalers. It becomes.
- the program of the present invention can be used as a program for plant use. Specifically, it is as follows.
- the program of this embodiment can be a program for plant management. That is, in this embodiment, the sample is a plant or soil. Specifically, the sample may be leaves, roots, sap, fruits, seeds, etc. of a plant, and may be a potted plant.
- the program causes the system to execute a process so as to detect and measure the state of the plant on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined processing of the present embodiment is a processing for making a data format suitable for plant management.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for plant management can be displayed on the display unit.
- Lactic acid in the soil promotes water absorption of plants. Therefore, the water absorption of plants changes according to the amount of lactic acid in the soil. Therefore, in the present embodiment, the state of water absorption of the plant can be evaluated.
- the program of the present embodiment can propose the timing of adding nutrients and watering the plants in the flowerpot. Furthermore, when the pH is low, it becomes possible to suppress the growth of various germs in the plant. Therefore, by measuring the pH together with the amount of lactic acid, it becomes possible to suppress the growth of various germs.
- the program of this embodiment can be a program for indicators of soil management and hydroponics management. That is, in this embodiment, the sample is soil or water.
- the program causes the system to execute a process so as to detect and measure the state of the soil on which lactate dehydrogenase is acted on the acting part by a sensor and convert it into a signal.
- the program causes the system to execute the process so that the signal obtained in the measurement process is transferred from the output unit to the data processing unit.
- the program causes the system to execute the processing so that the data processing unit performs a predetermined processing on the signal obtained in the measurement processing.
- the predetermined treatment of the present embodiment is a treatment for making a data format suitable for an index of soil management and hydroponics management.
- the program causes the system to execute the process so that the predetermined display unit displays the result processed by the data processing unit.
- data in a data format suitable for the index of soil management and hydroponics management can be displayed on the display unit.
- Lactic acid in soil and hydroponic water promotes water absorption of plants. Therefore, the water absorption of plants changes depending on the amount of lactic acid in the soil and hydroponic water. Therefore, in the present embodiment, it is possible to evaluate the water absorption state of plants existing in soil and hydroponic water.
- the program of the present embodiment can propose the timing of addition of nutrients to plants, the timing of watering, and the timing of topdressing. Furthermore, when the pH is low, it becomes possible to suppress the growth of various germs in the plant. Therefore, by measuring the pH together with the amount of lactic acid, it becomes possible to suppress the growth of various germs.
- the mainstream of plant management is not based on data, such as adding fertilizer according to the time such as the season and adding water or nutrients when the condition of the plant deteriorates.
- the lactate dehydrogenase of the present invention has sufficient thermal stability, simple and continuous lactate monitoring can be realized.
- the lactic acid level contained in the soil becomes low, it is possible to provide a system for calculating the amount of saccharides and lactic acid added that can be assimilated by lactic acid bacteria in order to enhance the antibacterial property in the soil.
- a system for calculating the type and amount of alkaline fertilizer added is provided.
- the present invention has 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or identity with the amino acid sequence shown in SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, or SEQ ID NO: 12. It also relates to lactate dehydrogenase, which has a 95% or higher amino acid sequence, and the nucleic acid encoding it.
- the present invention relates to the nucleotide sequences set forth in SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, or SEQ ID NO: 13 and 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83% , 84%, 85%, 86%, 87%, 88%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more.
- Provided is a DNA encoding a protein having a base sequence having sequence identity and having lactic acid activity.
- LDH gene To obtain the gene encoding LDH, a commonly used gene cloning method is usually used. For example, chromosomal DNA or mRNA can be extracted from microbial cells having LDH-producing ability or various cells by a conventional method, for example, the method described in Current Protocols in Molecular Biology (WILEY Interscience, 1989). Furthermore, cDNA can be synthesized using mRNA as a template. Using the chromosomal DNA or cDNA thus obtained, a library of chromosomal DNA or cDNA can be prepared.
- a method of synthesizing an appropriate probe DNA based on the above-mentioned LDH amino acid sequence and selecting the LDH gene from a library of chromosomal DNA or cDNA using this, or a method of selecting an appropriate primer DNA based on the above-mentioned amino acid sequence is amplified by an appropriate polymerase chain reaction (PCR method) such as the 5'RACE method or the 3'RACE method, and these DNA fragments are ligated.
- PCR method polymerase chain reaction
- a DNA containing the full length of the LDH gene of interest can be obtained.
- LDH genes may be linked or inserted into various vectors, or may be integrated into a chromosome or genome.
- kits such as TA Cloning Kit (Invitrogen) and In-Fusion HD Cloning Kit (Clontech); pUC119 (Takarabio), pUC18 (Takarabio), Commercially available plasmid vector DNAs such as pBR322 (Takara Bio), pBluescript SK + (Stratagene), pYES2 / CT (Invitrogen); and commercially available bacterial plunger vector DNAs such as ⁇ EMBL3 (Stratagene) can be used.
- the recombinant DNA is used to transform a host organism such as Escherichia coli, preferably Escherichia coli JM109 strain (Takara Bio Inc.) or Escherichia coli DH5 ⁇ strain (Takara Bio Inc.).
- Recombinant DNA contained in the obtained transformant is purified using QIAGEN plasmid Mini Kit (Qiagen) or the like.
- Qiagen QIAGEN plasmid Mini Kit
- it is preferable to use a host organism transformed with recombinant DNA containing the LDH gene for example, Escherichia coli, yeast, mold cells, filamentous fungi, etc., as the host for producing LDH.
- the present invention also relates to a host cell having the above nucleic acid and a method for producing lactate dehydrogenase, which comprises culturing the host cell.
- this strain may be cultured by a usual solid culture method, but it is possible. It is preferable to use the liquid culture method for culturing.
- a medium for culturing the above strain for example, one or more nitrogen sources such as yeast extract, tripton, peptone, meat extract, corn steep liquor or leachate of soybean or wheat bran, sodium chloride, and phosphoric acid first.
- inorganic salts such as potassium, dipotassium phosphate, magnesium sulfate, magnesium chloride, ferric chloride, ferrous sulfate or manganese sulfate, and if necessary, add sugar raw materials, vitamins, etc. as appropriate. Is used. It is appropriate to adjust the initial pH of the medium to pH 7-9. Any conditions can be used for culturing, and for example, a culturing temperature of 20 to 42 ° C., preferably a culturing temperature of about 30 ° C. for 4 to 24 hours, and more preferably a culturing temperature of about 30 ° C.
- LDH can be collected from the culture by using a usual enzyme collection means.
- the cells are subjected to ultrasonic destruction treatment, grinding treatment, etc. by a conventional method, or this enzyme is extracted using a lytic enzyme such as lysozyme, or the bacterium is shaken or left to stand in the presence of toluene or the like. This enzyme can be excreted from the cells. Then, this solution is filtered, centrifuged, etc.
- nucleic acid is removed with streptomycin sulfate, protamine sulfate, manganese sulfate, etc., and then ammonium sulfate, alcohol, acetone, etc. are added thereto. Fractionation is performed and the precipitate is collected to obtain the crude enzyme of LDH.
- an LDH purified enzyme preparation from the above crude enzyme of LDH, for example, a gel filtration method using Sephadex, Superdex or Ultrogel; an adsorption elution method using an ion exchanger; electrophoresis using a polyacrylamide gel or the like. Method; Adsorption elution method using hydroxyapatite; Precipitation method such as sucrose density gradient centrifugation method; Affinity chromatography method; Fractionation method using molecular sieving membrane or hollow yarn membrane, etc. are appropriately selected, or a combination thereof is carried out. By doing so, a purified LDH enzyme preparation can be obtained. In this way, LDH with the desired improved stability can be obtained.
- the lactate dehydrogenase of the present invention has about 20% or more, 30% or more, 40% or more, 50% or more, 60% of the initial activity when allowed to elapse at about 30 to 37 ° C. for 10 days in the solution (A).
- flavin-dependent lactate dehydrogenase maintaining 70% or more, 80% or more, 90% or more or 95% or more; when allowed to pass at about 30 to 37 ° C. for 3 days or more in the solution (B).
- Flavin-dependent lactate dehydrogenase which maintains about 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more or 95% or more of the initial activity, Alternatively, when allowed to elapse at about 30 to 37 ° C. for 15 hours or more in the solution (C), about 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more of the initial activity. , 80% or more, 90% or more, or 95% or more may be flavin-dependent lactate dehydrogenase.
- the lactate dehydrogenase of the present invention may be a flavin-dependent lactate dehydrogenase that maintains 70% or more activity even after 15 hours from the time of use.
- the buffer material (buffer solution) that can be used in the reaction solution of LDH include a borate buffer containing boric acid and / or a salt thereof, a Tris hydrochloric acid buffer, a phosphoric acid containing phosphoric acid and / or a salt thereof.
- a buffer such as a potassium phosphate buffer or a sodium phosphate buffer, an organic acid buffer and / or an organic acid buffer containing a salt thereof, such as a tricarboxylic acid buffer and / or a tricarboxylic acid buffer containing a salt thereof, for example.
- a citrate buffer containing citrate and / or a salt thereof, a monocarboxylic acid buffer and a monocarboxylic acid buffer containing a salt thereof, for example, a buffer such as an acetate buffer and an acetate buffer containing a salt thereof. can be mentioned.
- ACES N- (2-acetamide) -2-aminoethanesulfonic acid
- BES N, N-bis (2-hydroxyethyl) -2) -Aminoethanesulfonic acid
- Bicin N, N-bis (2-hydroxyethyl) glycine
- Bis-Tris bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane
- CHES N-cyclohexyl-2-) Amino ethane sulfonic acid
- EPPS 4-- (2-hydroxyethyl) -1-piperazin propane sulfonic acid
- HEPES (4-2-hydroxyethyl-1-piperazine ethane sulfonic acid
- HEPPSO N- (hydroxyethyl)) Piperazin-N'-2-hydroxypropanesulfonic acid
- MES 2- (N-morpholino) ethanesulfonic acid
- MES 2- (N-morpholino
- Example 1 (1) Preparation of recombinant plasmid pKK223-3-ScLDH DNA and pKK223-3-PkLDH DNA Biochem. J. As described in 258, 255-259 (1989), the 506 amino acids shown in SEQ ID NO: 1 from which the amino acids at positions 2 to 85 have been removed from the 591 amino acids which are the amino acid sequences of the lactic acid dehydrogenase (ScLDH) derived from Saccharomyces cerevisiae. The gene of 1521 bp (including the stop codon TAA) represented by SEQ ID NO: 2 encoding the above was obtained as cDNA by PCR of a gene fragment which is a conventional method.
- ScLDH lactic acid dehydrogenase
- SEQ ID NO: 3 which is the amino acid sequence of Lactate dehydrogenase (PkLDH) derived from Pichia kudriavzevii, was compared with ScLDH, and the sequence encoding the 502 amino acid represented by SEQ ID NO: 4 from which positions 2 to 77 were removed.
- the gene of 1509 bp (including the stop codon TAA) represented by No. 5 was obtained as cDNA by PCR of a gene fragment which is a conventional method.
- a DNA construct was prepared by inserting the ScLDH gene or PkLDH gene, which is the target gene, into the multi-cloning site of the plasmid pKK223-3 by a conventional method.
- the ScLDH gene or PkLDH gene was attached to the kit using the In-Fusion HD Cloning Kit (manufactured by Clontech) at the In-Fusion Cloning Site at the multi-cloning site of pKK223-3.
- In-Fusion HD Cloning Kit manufactured by Clontech
- expression plasmids pKK223-3-ScLDH and pKK223-3-PkLDH were obtained.
- Escherichia coli JM109 was transformed with these plasmids, and Escherichia coli JM109 (pKK223-3-ScLDH) strain and Escherichia coli JM109 (pKK223-3-PkLDH) strain were added to 3 ml of LB-amp medium [1% (w / v). ) Bacttrypton, 0.5% (w / v) peptone, 0.5% (w / v) NaCl, 50 ⁇ g / ml ampicillin] was inoculated and cultured with shaking at 37 ° C. for 16 hours. Got
- Each of the obtained cultured cells was washed with 10 mM potassium phosphate buffer (pH 7.5), suspended in the buffer, ultrasonically crushed, and centrifuged at 20,000 ⁇ g for 10 minutes. Then, 0.6 ml of a crude enzyme solution containing ScLDH or PkLDH was prepared.
- LDH activity Using the crude enzyme solution containing ScLDH or PkLDH described above, the oxidation activity for L-lactic acid was measured by the method shown in the activity measurement method below.
- the LDH of the present invention catalyzes the reaction of oxidizing L-lactic acid to produce pyruvic acid. This may be referred to as LDH activity for convenience.
- the LDH activity of PkLDH of the present invention can be measured by utilizing this principle of action, for example, using the following measurement system using potassium ferricyanide as an electron acceptor.
- the degree of disappearance of the above "potassium ferricyanide” can be detected as the amount of change in absorbance at a wavelength of 420 nm, and the enzyme activity can be determined based on this amount of change.
- LDH activity can be measured according to the following procedure. 1M potassium phosphate buffer (pH 7.5) 0.15 mL, 0.1 M L-lactic acid solution 0.15 mL, 30 mM potassium ferricyanide solution 0.075 mL, ultrapure water 1.075 mL are mixed and kept warm at 30 ° C for 5 minutes. do. Then 0.05 mL of the enzyme sample solution is added and the reaction is started. The absorbance at the start of the reaction and over time is measured, the amount of decrease in absorbance at 420 nm ( ⁇ A420) with the progress of the enzymatic reaction per minute is determined, and the LDH activity is calculated according to the following formula. At this time, LDH activity defines 1 U as the amount of enzyme that reduces 1 ⁇ mol of potassium ferricyanide per minute in the presence of L-lactic acid at a concentration of 10 mM at 30 ° C.
- 1.5 is the liquid volume of the reaction reagent + enzyme reagent (mL)
- 1.01 is the mmol molecular absorption coefficient (cm 2 / ⁇ mol) under the present activity measurement conditions
- 0.05 is the liquid volume of the enzyme solution.
- ML 1.0 is the optical path length (cm) of the cell
- ⁇ A420blank is the absorbance at 420 nm per minute when the reaction was started by adding 10 mM phosphate buffer (pH 7.5) instead of the enzyme sample solution.
- the amount of decrease in, df represents a dilution factor.
- Example 2 Temporal stability
- the above crude enzyme solution was diluted to a 100 mM potassium phosphate buffer solution (pH 6.0) containing 0.07% BSA as the final concentration, and the temperature stability was examined.
- the LDH enzyme solution prepared in (2) of Example 1 was diluted to 6 U / ml, and each temperature (35 ° C, 40 ° C, 45 ° C, 50 ° C, 55 ° C, 60 ° C, 65). After treatment at (° C.) for 10 minutes, LDH activity was measured, and the residual activity rate was measured as compared with LDH activity before treatment.
- a similar test was also performed on ScLDH for comparison. The results are shown in FIG. From the results, it was found that ScLDH is unstable at 45 ° C., but PkLDH is stable even after heat treatment at 55 ° C.
- FIG. 3A is a graph of the residual activity rate after each time elapsed, where the residual activity rate when the elapsed time is zero time is 100%. As a result, it was found that the residual activity rate of PkLDH heated to a certain extent (37 ° C. in this example) was improved by a certain period during storage (FIG.
- FIG. 3B is a graph of the residual activity rate after each time elapses, where the activity rate at the reference time is 100% when 15 hours from the start of storage is set as the reference time.
- PkLDH retains 99% activity even after 245 hours have passed from the start of storage (230 hours after the reference time), and after 15 hours, the residual activity rate becomes constant and is about 10 days at 37 ° C. It was not deactivated even when stored and was very stable (Fig. 3B).
- the residual activity rate of ScLDH began to decrease remarkably from the start of storage, the residual activity rate after 21 hours (6 hours after the reference time) was 62%, and the activity after 65 hours (50 hours after the reference time).
- the survival rate was 0%, which was unstable. Further, even if the amount of ScLDH enzyme was evaluated to be 20 U / ml, the stability was not significantly improved.
- Example 3 Purification of enzyme
- the crude enzyme solution of PkLDH obtained in (2) of Example 1 was subjected to 1 ml of Q Sepharose Fast Flow resin (manufactured by GE Healthcare) equilibrated with 20 mM potassium phosphate buffer (pH 7.5), and the resin was applied. Was adsorbed on. Proteins that did not adsorb to the resin were eluted with the same buffer. Subsequently, it was washed with 20 mM potassium phosphate buffer (pH 7.5) containing 50 mM sodium chloride and 20 mM potassium phosphate buffer (pH 7.5) containing 200 mM sodium chloride.
- the adsorbed PkLDH was eluted with a 20 mM potassium phosphate buffer (pH 7.5) containing 500 mM sodium chloride.
- the obtained crude enzyme solution of PkLDH was applied to a HiRoad 26/10 Q Sepharose HP column (manufactured by GE Healthcare) equilibrated with a 20 mM potassium phosphate buffer solution (pH 7.5) containing 150 mM sodium chloride, and one column was provided. A fraction containing the protein of interest was collected by running a volume of buffer solution.
- the recovered enzyme solution was dialyzed against 10 mM potassium phosphate buffer (pH 7.5), adsorbed on a Hiscreen Capto Q column (manufactured by GE Healthcare) equilibrated with the buffer, and then 500 mM NaCl / 10 mM phosphorus. PkLDH adsorbed on the resin was eluted and recovered by gradually increasing the NaCl concentration with a gradient to potassium phosphate buffer (pH 7.5). The obtained fraction was analyzed by SDS-PAGE and confirmed to be purified to a purity free of other contaminating proteins, and used as a purified preparation of PkLDH. The thermal stability was equivalent to that of the crude enzyme solution.
- Example 4 The pH stability was examined using the purified PkLDH enzyme solution (10 U / mL) obtained in Example 3. After heat treatment at 55 ° C. for 15 minutes using 100 mM potassium phosphate buffer (pH 6.0-pH 7.5), the enzyme was maintained in each buffer, and the other enzymes were used in Example 1 ( The activity was measured according to the activity measuring method described in 3). The condition with the highest activity in the activity value after the treatment was set to 100%, and the relative value was determined for the activity value under the other conditions. The results are shown in FIG. As a result, it was the most stable at pH 6.5, followed by 92% relative activity (%) at pH 6.0.
- the optimum active pH was examined using the purified PkLDH enzyme solution (10 U / mL) obtained in Example 3. Using 100 mM potassium phosphate buffer (pH 6.0-pH 7.5), an enzymatic reaction was carried out at a temperature of 30 ° C. at each pH, and the relative activity (%) was compared. The results are shown in FIG. As a result, the optimum active pH of the FMN-dependent lactate dehydrogenase of the present invention was shown to be the highest in the pH range of 6.5 to 7.5. It is considered that there is a possibility that good activity is maintained even at pH 8.0.
- Example 5 Quantification of L-lactic acid by printed electrode
- SCREEN-PRINTED ELECTRODES manufactured by DropSens, product number DRP-110
- DRP-CAC dedicated connector
- lactic acid can also be quantified by electrochemical measurement.
- Example 6 (4) Preparation of recombinant plasmid pKK223-3-CaLDH DNA and pKK223-3-OgLDH DNA and production of each LDH
- SEQ ID NO: 6 which is the amino acid sequence of lactate dehydrogenase (CaLDH) derived from Candida inconspirua
- the 505 amino acids shown in SEQ ID NO: 7 with the 2-67 positions removed are encoded by 1518 bp shown in SEQ ID NO: 8.
- Gene including stop codon TAA was obtained as cDNA by PCR of the gene fragment, which is a conventional method.
- SEQ ID NO: 9 which is the amino acid sequence of lactate dehydrogenase (OgLDH) derived from Ogataea parapolymerase
- SEQ ID NO: 10 the 503 amino acids shown in SEQ ID NO: 10 from which positions 2 to 56 have been removed are encoded by SEQ ID NO: 11.
- the 1512 bp gene (including the stop codon TAA) shown in (1) was obtained as a cDNA by PCR of a gene fragment, which is a conventional method.
- Example 2 In the same manner as in Example 1, a DNA construct in which the target gene CaLDH gene or OgLDH gene was inserted into the multicloning site of the plasmid pKK223-3 by a conventional method was prepared, and expression plasmids (pKK223-3-CaLDH and pKK223) were prepared. -3-OgLDH) was obtained. Escherichia coli BL21 (pKK223-3-CALDH) strain transduced with pKK223-3-CaLDH and Escherichia coli BL21 (pKK223-3-OgLDH) strain transduced with pKK223-3-OgLDH so as to have a final concentration of 0.1 mM.
- Example 7 Temporal stability Similar to Example 2, long-term stability at 37 ° C. was examined. However, 100 mM potassium phosphate buffer (pH 6.0) containing 0.07% BSA as the final concentration, CaldH or OgLDH was diluted to about 20 U / ml and stored for each time. Then, the residual activity rate after each time elapsed was measured. The results are shown in FIG. 3 (A). CalDH retains 72% activity 140 hours after the start of storage, and OgLDH retains 77% activity 140 hours after the start of storage, which is very stable compared to ScLDH. Met.
- Example 8 Preparation of recombinant plasmid pKK223-3-ThrLDH DNA and production of each LDH. It is shown by SEQ ID NO: 13, which encodes the 499 amino acid represented by SEQ ID NO: 12, which is the amino acid sequence of lactate dehydrogenase (ThLDH) derived from Thermothelomyces thermophilus.
- SEQ ID NO: 13 which encodes the 499 amino acid represented by SEQ ID NO: 12, which is the amino acid sequence of lactate dehydrogenase (ThLDH) derived from Thermothelomyces thermophilus.
- the 1500 bp gene (including the stop codon TAA) was obtained as a DNA by PCR of the gene fragment, which is a conventional method.
- a DNA construct was prepared by inserting the ThLDH gene, which is the target gene, into the multicloning site of the plasmid pKK223-3 by a conventional method, and an expression plasmid (pKK223-3-ThhLDH) was obtained.
- Escherichia coli BL21 (pKK223-3-ThhLDH) strain transduced with pKK223-3-ThhLDH was cultured at 30 ° C. for 24 hours in 3 ml of LB-amp medium supplemented with IPTG so as to have a final concentration of 1 mM.
- Each of the obtained cultured cells was washed with 10 mM potassium phosphate buffer (pH 7.5), suspended in the buffer, ultrasonically crushed, and centrifuged at 20,000 ⁇ g for 10 minutes. Then, 0.6 ml of a crude enzyme solution containing ThLDH was prepared.
- Example 9 (Temperature stability) Similar to Example 2, long-term stability at 37 ° C. was examined. A 100 mM potassium phosphate buffer (pH 6.0) containing 0.07% BSA as a final concentration and ThLDH were diluted to about 20 U / ml and stored for each time. Then, the residual activity rate after each time elapsed was measured. ThLDH retained 74% activity even after 89 hours from the start of storage, and was very stable as compared with ScLDH. That is, it can be said that ThLDH maintains 70% or more of the initial activity when it is allowed to pass at 37 ° C. for at least 3 days or more.
- Example 10 Preparation of PkLDH mutant A mutant in which the N-terminal region of PkLDH was further deleted was constructed. First, in order to prepare a mutant (PkLDH-96) in which the amino acids at positions 2 to 95 in SEQ ID NO: 4 have been deleted, the recombinant plasmid pKK223-3-PkLDH obtained in Example 1 was used as a template for the sequence. The PCR reaction was carried out under the following conditions using the synthetic oligonucleotides Nos. 14 and 15 and KOD One PCR Master Mix (manufactured by Toyobo Co., Ltd.).
- Escherichia coli JM109 was transformed with the reaction solution and developed on LB-amp agar medium.
- the recombinant plasmid was extracted and purified by the same method as in Example 1 to obtain 2.5 ⁇ g of DNA.
- the base sequence of the DNA encoding PkLDH-96 in the plasmid was determined using a multicapillary DNA analysis system Applied Biosystems 3130xl Genetic Analyzer (manufactured by Life Technologies), and as a result, a DNA construct encoding PkLDH-96 was determined. Obtained.
- PkLDH-103 a synthetic oligonucleotide of SEQ ID NOs: 14 and 22, and a variant (PkLDH-104) lacking the amino acids at positions 2 to 103 in SEQ ID NO: 4 are prepared.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 24, 25, 26, and 27 using pKK223-3-PkLDH as a template.
- a PCR reaction was carried out under the following conditions using the recombinant plasmid pKK223-3-PkLDH as a template and the synthetic oligonucleotides of SEQ ID NOs: 24 and 25, KOD One PCR Master Mix (manufactured by Toyobo Co., Ltd.). ..
- the obtained PCR product was treated with the restriction enzyme DpnI, the remaining template DNA was cleaved, and then Escherichia coli JM109 was transformed and developed on an LB-amp agar medium.
- the recombinant plasmid was extracted and purified by the same method as in Example 1 to obtain 2.5 ⁇ g of DNA.
- the nucleotide sequence of the DNA encoding the PkLDH mutant in the plasmid was determined using a multicapillary DNA analysis system Applied Biosystems 3130xl Genetic Analyzer (manufactured by Life Technologies).
- a PCR reaction was carried out under the same conditions using the recombinant plasmid pKK223-3-PkLDH / L386R as a template and the synthetic oligonucleotides of SEQ ID NOs: 26 and 27 and KOD One PCR Master Mix (manufactured by Toyobo Co., Ltd.). , 2.5 ⁇ g of DNA was obtained.
- the base sequence of the DNA encoding the PkLDH mutant in the plasmid was determined using a multicapillary DNA analysis system Applied Biosystems 3130xl Genetic Analyzer (manufactured by Life Technologies), and leucine at position 386 of the amino acid sequence shown in SEQ ID NO: 4.
- L386R / T461R / D464R means that leucine at position 386 of the amino acid sequence of SEQ ID NO: 4 is replaced with arginine, threonine at position 461 is replaced with arginine, and aspartic acid at position 464 is replaced with arginine.
- the "/" symbol means that it has all of its respective substitutions.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 28 and 29 using pKK223-3-PkLDH as a template, and PkLDH / which is a mutant in which phenylalanine at position 161 of the amino acid sequence shown in SEQ ID NO: 4 was replaced with leucine.
- a DNA construct encoding F161L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 30 and 31 using pKK223-3-PkLDH as a template, and PkLDH / which is a mutant in which phenylalanine at position 187 of the amino acid sequence shown in SEQ ID NO: 4 was replaced with leucine.
- a DNA construct encoding F187L was obtained. Further, PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 32 and 33 using pKK223-3-PkLDH as a template, and PkLDH / which is a mutant in which phenylalanine at position 428 of the amino acid sequence shown in SEQ ID NO: 4 was replaced with leucine. A DNA construct encoding F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 32 and 33 using pKK223-3-PkLDH-97 as a template, and phenylalanine at the position corresponding to position 428 of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 34 and 35 using PkLDH-97 / F428L as a template, and leucine at the position corresponding to the 194th position of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 36 and 37 using PkLDH-97 / F428L as a template, and leucine at the position corresponding to position 222 of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 38 and 39 using PkLDH-97 / F428L as a template, and the alanine at the position corresponding to the 274th position of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 40 and 41 using PkLDH-97 / F428L as a template, and leucine at the position corresponding to the 277th position of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 42 and 43 using PkLDH-97 / F428L as a template, and phenylalanine at the position corresponding to the 313th position of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 44 and 45 using PkLDH-97 / F428L as a template, and isoleucine at the position corresponding to position 314 of the amino acid sequence shown in SEQ ID NO: 4 in PkLDH-97 / F428L was obtained.
- PkLDH / F428L was prepared in order to prepare a mutant (PkLDH-3 / F428L) in which the amino acid at position 2 in SEQ ID NO: 4 was deleted.
- PCR was performed using the synthetic oligonucleotides of SEQ ID NOs: 14 and 54 as a template, and as a result, a DNA construct encoding PkLDH-3 / F428L was obtained.
- the obtained Escherichia coli BL21 strain transduced with plasmids encoding various PkLDH mutants was cultured at 30 ° C. for 24 hours in 3 ml of LB-amp medium supplemented with IPTG so as to have a final concentration of 1 mM.
- Each of the obtained cultured cells was washed with 10 mM potassium phosphate buffer (pH 7.5), suspended in the buffer, ultrasonically crushed, and centrifuged at 20,000 ⁇ g for 10 minutes. To prepare 0.6 ml of a crude enzyme solution containing various PkLDH variants.
- the activity of the crude enzyme solution was 0.3 to 6 times higher than that of the wild type PkLDH for 13 types of mutants (PkLDH-76 to PkLDH-110) from which the N-terminal was deleted.
- the activity of the crude enzyme solution was 2 to 11 times higher than that of PkLDH / F428L for 9 types of mutants (PkLDH-3 / F428L to PkLDH-11 / F428L) from which the N-terminal was deleted.
- Example 11 Temporal stability
- the crude enzyme solution (PkLDH-96 to PkLDH-104) prepared in Example 10 was diluted to a 150 mM potassium phosphate buffer solution (pH 7.5) containing 0.15% BSA as the final concentration to improve the temperature stability.
- the LDH enzyme solution which is the N-terminal deleted mutant prepared in Example 10 was diluted to 6 U / ml, treated at 55 ° C. for 15 minutes, and then the LDH activity was measured to measure the LDH before treatment. The residual activity rate was measured in comparison with the activity.
- a similar test was also performed on PkLDH for comparison. The results are shown in FIG.
- PkLDH-96 to PkLDH-104 had a higher residual activity rate and higher thermal stability than PkLDH.
- other N-terminal deleted mutants PkLDH-76, PkLDH-84, PkLDH-92, PkLDH-110, PkLDH-3 / F428L, PkLDH-4 / F428L, PkLDH-5 / F428L, PkLDH-6 / F428L, PkLDH-7 / F428L, PkLDH-8 / F428L, PkLDH-9 / F428L, PkLDH-10 / F428L, PkLDH-11 / F428L) were similarly treated at 50 ° C.
- Example 10 the crude enzyme solution prepared in Example 10 (PkLDH-97 / F428L / L194A, PkLDH-97 / F428L / L222Y, PkLDH-97 / F428L / A274S, PkLDH-97 / F428L / L277S, PkLDH-97 / F428L / F313A, PkLDH-97 / F428L / I314S) was used for treatment at 50 ° C. for 15 minutes.
- PkLDH-104 The activity of PkLDH-104 was maintained at 111% even after the lapse, 97% after the lapse of 43 hours from the start of storage, 99% after the lapse of 72 hours, and 88% after the lapse of 171 hours.
- PkLDH / L386R / T461R / D464R retained 96% activity even after 89 hours from the start of storage, and PkLDH / F428L was 99% after 43 hours, 107% after 72 hours, and after 171 hours. Also retained 94% activity and was very stable compared to ScLDH. That is, it can be said that these mutants maintain 70% or more of the initial activity when allowed to pass at 37 ° C. for at least 3 days or more.
- PkLDH-98, PkLDH-99, PkLDH-100, PkLDH-101, PkLDH-102, PkLDH-103, PkLDH / F161L and PkLDH / F187L also have higher thermal stability at 55 ° C. than PkLDH. Therefore, it is highly probable that the long-term stability at 37 ° C. is also very stable as compared with ScLDH.
- Example 12 Quantification of L-lactic acid by PkLDH-immobilized electrode
- L-lactic acid was quantified using an electrode on which the purified PkLDH enzyme solution obtained in Example 3 was immobilized.
- 12 U of PkLDH was applied and dried on the working electrode of SCREEN-PRINTED ELECTRODES (manufactured by DropSens, product number DRP-C110) on which the working electrode of carbon was printed.
- 3 ⁇ L of 2% poly (ethylene glycol) diglycidyl ether (Mn: 6000, manufactured by Sigma) was applied and reacted at 4 ° C. for 22 hours. It was washed with ultrapure water to obtain a PkLDH-immobilized electrode.
- DRP-CAC dedicated connector
- BAS ALS electrochemical analyzer 814D
- platinum electrode 0.1 mg / ml Lindschedler' Three electrodes were immersed in 10 ml of PBS (pH 7.4) containing s Green Leuco Base (manufactured by Tokyo Kasei Co., Ltd.). +200 mV (vs Ag / AgCl) was applied, and the response current value when the L-lactic acid solution was added at regular intervals was recorded. The result is shown in FIG. It was shown that when 1 to 7 mM L-lactic acid was added, the response current increased in a lactic acid concentration-dependent manner, and L-lactic acid could be quantified.
- DRP-CAC dedicated connector
- a device for evaluating the state of a sample including an action part for allowing FMN-LDH to act on the sample of the present invention and a sensor for detecting the state of the sample on which FMN-LDH is acted, and a sample using the device.
- interstitial fluid blood, urine, tears, sweat, saliva, skin, flesh, eyeballs, cornea, gastric fluid, food and drink, brews, chemicals. Since lactic acid in a lactic acid-containing composition containing water and soil can be measured stably, accurately and easily over a long period of time, it is possible to manage the health of humans and animals, or to manufacture foods and drinks, brewed products, chemical products, etc. It is useful in control, quality control, etc.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
(1)
検体の状態を評価するためのデバイスであって、
検体に乳酸デヒドロゲナーゼを作用させるための作用部と、
乳酸デヒドロゲナーゼを作用させた検体の状態を感知するためのセンサであって、作用部での検体の状態を感知することが可能なように配置されるセンサと
を含む、デバイス。
(2)
センサからの信号を出力するための出力部をさらに含む、(1)記載のデバイス。
(3)
(2)記載のデバイスと、
デバイスの出力部に接続され、センサからの信号を処理するためのデータ処理ユニットと
を含む、システム。
(4)
検体の状態を、デバイス及びデータ処理ユニットを含むシステムによって評価するためのプログラムであって、
デバイスが、
検体に乳酸デヒドロゲナーゼを作用させるための作用部と、
乳酸デヒドロゲナーゼを作用させた検体の状態を感知するためのセンサであって、作用部での検体の状態を感知することが可能なように配置されるセンサと、
センサからの信号を出力するための出力部と
を含み、
データ処理ユニットが、デバイスの出力部に接続され、センサからの信号を処理するように構成され、
プログラムが、デバイスに対して、
センサにより、乳酸デヒドロゲナーゼを作用部において作用させた検体の状態を感知して測定し、信号に変換するための、測定処理と、
前記測定処理で得られた信号を出力部からデータ処理ユニットに対して転送するための、転送処理と、を実行させ、
プログラムが、前記データ処理ユニットに対して、前記測定処理で得られた信号に対して所定の処理をするための、データ処理を実行させる、プログラム。
(5)
(1)又は(2)記載のデバイス、又は(3)記載のシステムを用いる、検体の状態を評価する方法。
(6)
検体が、ヒトおよび非ヒト生物の体液、間質液、血液、尿、涙、汗、唾液、皮膚、肉、眼球、角膜、胃液、飲食品、醸造物、化成品、水、土壌を含む乳酸含有組成物である、(5)記載の方法。
(7)
検体の状態が、運動負荷に対する身体状態、疾病状態、乳酸量の変化を伴う醸造物の醸造状態、乳酸量の変化を伴う飲食品の熟成・追熟度合、乳酸量の変化を伴う化成品製造の乳酸含有割合、乳酸量の変化を伴う水、土壌中の乳酸量である、(5)又は(6)記載の方法。
(8)
検体の状態をモニタリングするためのデバイスであって、デバイスは、検体に、
(A)溶液中で、37℃にて10日間経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ、
(B)溶液中で、37℃にて3日間以上経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ、又は
(C)溶液中で、37℃にて15時間以上経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ
を作用させるための作用部を含む、デバイス。
(9)
(8)記載のデバイスがさらに出力部を含み、その出力部がデータ処理ユニットに接続される、システム。
(10)
(8)記載のデバイスまたは(9)記載のシステムを用いる、検体の状態をモニタリングする方法。
(11)
配列番号4で示されるアミノ酸配列における110~502位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、配列番号7で示されるアミノ酸配列における113~505位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、アミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、配列番号10で示されるアミノ酸配列における112~503位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、又は配列番号12で示されるアミノ酸配列における102~499位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列を含む、乳酸デヒドロゲナーゼ。
(12)
配列番号4、配列番号7、配列番号10、又は配列番号12に示されるアミノ酸配列又はそれとの同一性が70%以上のアミノ酸配列を有する、(11)記載の乳酸デヒドロゲナーゼ。
(13)
(11)又は(12)記載の乳酸デヒドロゲナーゼをコードする核酸。
(14)
(13)記載の核酸を有する、宿主細胞。
(15)
(14)記載の宿主細胞を培養することを含む、乳酸デヒドロゲナーゼの製造方法。
(16)
検体の状態を評価するための方法であって、
i)(11)又は(12)記載の乳酸デヒドロゲナーゼと検体を接触させる工程、及び
ii)乳酸を測定する工程
を含む、方法。
アミノ酸配列の同一性又は類似性は、GENETYX Ver.11(ゼネティックス社製)のマキシマムマッチングやサーチホモロジー等のプログラムまたはDNASIS Pro(日立ソリューションズ社製)のマキシマムマッチングやマルチプルアライメント等のプログラムにより計算することができる。アミノ酸配列同一性を計算するために、2以上のLDHをアライメントしたときに、該2以上のLDHにおいて同一であるアミノ酸の位置を調べることができる。こうした情報を基に、アミノ酸配列中の同一領域を決定できる。
また、2以上のLDHにおいて類似であるアミノ酸の位置を調べることもできる。例えばCLUSTALWを用いて複数のアミノ酸配列をアライメントすることができ、この場合、アルゴリズムとしてBlosum62を使用し、複数のアミノ酸配列をアライメントしたときに類似と判断されるアミノ酸を類似アミノ酸と呼ぶことがある。本発明の変異体において、アミノ酸置換はこのような類似アミノ酸の間の置換によるものであり得る。こうしたアライメントにより、複数のアミノ酸配列について、アミノ酸配列が同一である領域及び類似アミノ酸によって占められる位置を調べることができる。こうした情報を基に、アミノ酸配列中の相同性領域(保存領域)を決定できる。
例えば、配列番号4で示される乳酸デヒドロゲナーゼを基準として、138~140位、150~154位、185~194位、217~222位、243~245位、271~278位、280~283位、355~367位、398~401位、403~406位、425~433位、447~450位、455~457位は相同性領域に該当しうる。また、例えば、配列番号4で示される乳酸デヒドロゲナーゼを基準として、138~140位、150~154位、185~188位、191~194位、217~219位、243~245位、271~275位、280~283位、355~366位、398~400位、405~410位、425~431位、447~450位、455~457位は相同性領域に該当しうる。さらに、本発明の乳酸デヒドロゲナーゼの相同性領域におけるアミノ酸配列は、配列番号4における相同性領域のアミノ酸配列と75%以上、例えば80%以上、81%以上、82%以上、83%以上、84%以上、85%以上、86%以上、87%以上、88%以上、89%以上、90%以上、91%以上、92%以上、93%以上、94%以上、95%以上、96%以上、97%以上、98%以上、例えば99%以上の配列同一性を有する。
さらに、特に本発明の乳酸デヒドロゲナーゼが活性を保持するために重要なアミノ酸として、配列番号4で示される乳酸デヒドロゲナーゼにおける361位のヒスチジンや364位のアルギニンが挙げられる。図11-1、11-2に示される各乳酸デヒドロゲナーゼのアミノ酸配列のアライメントを用いることで、配列番号4以外の乳酸デヒドロゲナーゼにおける、これらの重要なアミノ酸位置に相当する位置を明らかにすることも可能である(図11-2中の矢印で示された位置)。なお、図11-1、11-2には配列番号4、配列番号7、配列番号10、又は配列番号12で示される乳酸デヒドロゲナーゼに加え、Ogataea polymorpha由来乳酸デヒドロゲナーゼのアミノ酸配列である558アミノ酸のうち、2~51位を除去した配列番号46で示される503アミノ酸(LDH-1)、Candida californica由来乳酸デヒドロゲナーゼのアミノ酸配列である558アミノ酸のうち、2~86位を除去した配列番号47で示される506アミノ酸(LDH-2)、Chaetomium globosum由来乳酸デヒドロゲナーゼのアミノ酸配列である配列番号48で示される502アミノ酸(LDH-3)、Madurella mycetomatis由来乳酸デヒドロゲナーゼのアミノ酸配列である配列番号49で示される499アミノ酸(LDH-4)を含めたアライメントを示す。
上述した合成分子としては、例えば、ポリエチレングリコールやアクリルアミドなどの親水性アクリル系分子が挙げられる。これらの中でも、ポリエチレングリコールジメタクリレートは、伸縮性高分子であり、細胞や生体組織への親和性だけでなく、伸縮性、粘弾性、堅牢性を向上することができるために好ましい。
また、生体分子としては、例えば、アルギン酸ナトリウムなどの多糖類、ゼラチンやシルクなどのタンパク質材料、コラーゲンなどの細胞外マトリクスなどが挙げられる。これらの中でも、タンパク質を多く含有する材料が好ましい。したがって、本実施形態の生体適合性ゲル材料としては、生体適合性を有する成分の一つとしてシルクフィブロインゲルを用いることが好ましい。タンパク質を多く含有するシルクフィブロインゲルを用いることにより、ゲル材料の表面では、生体適合性が高く、細胞の接着性の促進が観察されるほど、細胞毒性を少なくすることができる。
上述した合成分子及び生体分子は、高分子であってもよいし、低分子であってもよい。ここで、高分子の分子量(Mw)としては、当該高分子がゲル構造を構成可能であれば特に限定されず、例えば分子量が5,000~1,000,000Da程度の高分子を使用することができる。
センサとして、センサチップを用いても良い。図1(a)は本発明の一実施形態に関するセンサチップ10の模式図であり、図1(b)~図1(d)はセンサチップ10を構成する部材を示す模式図である。センサチップ10は、基材11上に配置した2以上の電極を備える。基材11は絶縁材料で構成される。図1(a)及び図1(b)においては、一例として、作用極1、対極3及び参照極5が基材11上に配置される。各電極は配線部7にそれぞれ電気的に接続し、配線部7は各電極とは配線方向の逆側に位置する端子9に電気的に接続する。作用極1、対極3及び参照極5は互いに離間して配置される。また、作用極1、対極3及び参照極5は、配線部7及び端子9と一体で構成されることが好ましい。また、対極3及び参照極5を一体型としてもよい。
また、工程ii)の乳酸を測定する工程は単回測定でもよいし、連続測定でも良い。工程ii)の測定する期間は、5秒、1分、5分、1時間、2時間、6時間、12時間、15時間、24時間、2日、5日、7日、10日あるいは14日でもよい。
本実施形態のプログラムは、牛肉の鮮度管理のためのプログラムであることができる。すなわち、本実施形態では、検体は牛肉である。
本実施形態のプログラムは、牛肉の熟成の管理と制御指標のためのプログラムであることができる。すなわち、本実施形態では、検体は牛肉である。
本実施形態のプログラムは、マグロ等の魚の鮮度管理のためのプログラムであることができる。すなわち、本実施形態では、検体はマグロ等の魚である。
本実施形態のプログラムは、マグロ等の魚の熟成の管理と制御指標のためのプログラムであることができる。すなわち、本実施形態では、検体はマグロ等の魚である。
本実施形態のプログラムは、上記以外の食品及び飲料のためのプログラムとして、例えば、ワインのマロラクティック発酵管理、日本酒やベーグルなどのパン、くずもちの発酵管理、ウイスキーの乳酸発酵管理、お茶の発酵管理、食品の安全性の指標等のためのプログラムであることができる。本実施形態のプログラムによれば、経験と勘に頼っていた、ワインや日本酒などの醸造酒の発酵管理を、乳酸値の他に、pH値、溶存酸素値などを指標にすることによって、適切な温度制御や発酵期間を得ることができる。
本実施形態のプログラムは、競走馬の管理のためのプログラムであることができる。すなわち、本実施形態では、検体は競走馬である。
本実施形態のプログラムは、競走馬の疲労度測定のためのプログラムであることができる。すなわち、本実施形態では、検体は競走馬である。
本実施形態のプログラムは、牛の健康管理、出荷時判定管理または肉牛の肉質制御のためのプログラムであることができる。すなわち、本実施形態では、検体は牛である。
本実施形態のプログラムは、乳牛の健康管理のためのプログラムであることができる。すなわち、本実施形態では、検体は乳牛である。
本実施形態のプログラムは、植物管理のためのプログラムであることができる。すなわち、本実施形態では、検体は植木や土壌である。検体として、具体的には、植物の葉、根、樹液、果実、種子等がありえ、鉢植えの植木であってもよい。
本実施形態のプログラムは、土壌管理、及び水耕栽培管理の指標のためのプログラムであることができる。すなわち、本実施形態では、検体は土壌又は水である。
LDHをコードする遺伝子を得るには、通常一般的に用いられている遺伝子のクローニング方法が用いられる。例えば、LDH生産能を有する微生物菌体や種々の細胞から常法、例えば、Current Protocols in Molecular Biology(WILEY Interscience,1989)記載の方法により、染色体DNAまたはmRNAを抽出することができる。さらにmRNAを鋳型としてcDNAを合成することができる。このようにして得られた染色体DNAまたはcDNAを用いて、染色体DNAまたはcDNAのライブラリーを作製することができる。
次いで、上記LDHのアミノ酸配列に基づき、適当なプローブDNAを合成し、これを用いて染色体DNAまたはcDNAのライブラリーからLDH遺伝子を選抜する方法、あるいは、上記アミノ酸配列に基づき、適当なプライマーDNAを作製して、5’RACE法や3’RACE法などの適当なポリメラーゼ連鎖反応(PCR法)により、LDHをコードする目的の遺伝子断片を含むDNAを増幅させ、これらのDNA断片を連結させて、目的のLDH遺伝子の全長を含むDNAを得ることができる。
また、上記菌株を培養する培地としては、例えば、酵母エキス、トリプトン、ペプトン、肉エキス、コーンスティープリカーまたは大豆もしくは小麦ふすまの浸出液等の1種以上の窒素源に、塩化ナトリウム、リン酸第1カリウム、リン酸第2カリウム、硫酸マグネシウム、塩化マグネシウム、塩化第2鉄、硫酸第2鉄または硫酸マンガン等の無機塩類の1種以上を添加し、さらに必要により糖質原料、ビタミン等を適宜添加したものが用いられる。
なお、培地の初発pHは、pH7~9に調整するのが適当である。
また、培養は任意の条件を用いることができるが、例えば、20~42℃の培養温度、好ましくは30℃前後の培養温度で4~24時間、さらに好ましくは30℃前後の培養温度で8~16時間、通気攪拌深部培養、振盪培養、静置培養等により実施することができる。
培養終了後、該培養物よりLDHを採取するには、通常の酵素採取手段を用いて得ることができる。例えば、常法により菌体を、超音波破壊処理、磨砕処理等するか、またはリゾチーム等の溶菌酵素を用いて本酵素を抽出するか、またはトルエン等の存在下で振盪もしくは放置して溶菌を行わせ、本酵素を菌体外に排出させることができる。そして、この溶液を濾過、遠心分離等して固形部分を除去し、必要によりストレプトマイシン硫酸塩、プロタミン硫酸塩または硫酸マンガン等により核酸を除去したのち、これに硫安、アルコール、アセトン等を添加して分画し、沈澱物を採取し、LDHの粗酵素を得る。
本発明の乳酸デヒドロゲナーゼは、(A)溶液中で、約30~37℃にて10日間経過させた時に、初発活性の約20%以上、30%以上、40%以上、50%以上、60%以上、70%以上、80%以上、90%以上又は95%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ;(B)溶液中で、約30~37℃にて3日間以上経過させた時に、初発活性の約20%以上、30%以上、40%以上、50%以上、60%以上、70%以上、80%以上、90%以上又は95%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ、又は(C)溶液中で、約30~37℃にて15時間以上経過させた時に、初発活性の約20%以上、30%以上、40%以上、50%以上、60%以上、70%以上、80%以上、90%以上又は95%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼであってよい。また、本発明の乳酸デヒドロゲナーゼは、使用に供してから15時間後を起点としても、70%以上活性を維持しているフラビン依存性乳酸デヒドロゲナーゼであってよい。
LDHの反応溶液に用いることができる緩衝材(緩衝液)としては、例えば、ホウ酸及び/又はその塩を含むホウ酸緩衝剤、トリス塩酸緩衝剤、リン酸及び/又はその塩を含むリン酸緩衝剤、例えばリン酸カリウム緩衝剤又はリン酸ナトリウム緩衝剤、有機酸緩衝剤及び/又はその塩を含む有機酸緩衝剤、例えばトリカルボン酸緩衝剤及び/又はその塩を含むトリカルボン酸緩衝剤、例えばクエン酸及び/又はその塩を含むクエン酸緩衝剤、モノカルボン酸緩衝剤及び/又はその塩を含むモノカルボン酸緩衝剤、例えば酢酸緩衝剤及び/又はその塩を含む酢酸緩衝剤等の緩衝剤が挙げられる。また、本発明のキット等に用いることのできる緩衝剤としては、ACES(N-(2-アセトアミド)-2-アミノエタンスルホン酸)、BES(N,N-ビス(2-ヒドロキシエチル)-2-アミノエタンスルホン酸)、Bicin(N,N-ビス(2-ヒドロキシエチル)グリシン)、Bis-Tris(ビス(2-ヒドロキシエチル)イミノトリス(ヒドロキシメチル)メタン)、CHES(N-シクロヘキシル-2-アミノエタンスルホン酸)、EPPS(4-(2-ヒドロキシエチル)-1-ピペラジンプロパンスルホン酸)、HEPES(4-2-ヒドロキシエチル-1-ピペラジンエタンスルホン酸)、HEPPSO(N-(ヒドロキシエチル)ピペラジン-N'-2-ヒドロキシプロパンスルホン酸)、MES(2-(N-モルホリノ)エタンスルホン酸)、MOPS(3-(N-モルホリノ)プロパンスルホン酸)、MOPSO(2-ヒドロキシ-3-モルホリノプロパンスルホン酸)、PIPES(ピペラジン-N,N'-ビス(2-エタンスルホン酸))、POPSO(ピペラジン-1,4-ビス(2-ヒドロキシプロパンスルホン酸))、TAPS(N-トリス(ヒドロキシメチル)メチル-3-アミノプロパンスルホン酸)、TAPSO(3-[N-トリス(ヒドロキシメチル)メチルアミノ]-2-ヒドロキシプロパンスルホン酸)、TES(N-トリス(ヒドロキシメチル)メチル-2-アミノエタンスルホン酸)、トリシン(N-トリス(ヒドロキシメチル)メチルグリシン)及び/又はそれらの塩等を含むグッド緩衝剤が挙げられる。LDHを反応させる温度としては、20~60℃であればよく、好ましくは30~55℃の範囲内であればよい。LDHを反応させるpHは3~10の範囲内であればよく、好ましくは6~10の範囲内であればよい。
(1)組換え体プラスミドpKK223-3-ScLDH DNA及びpKK223-3-PkLDH DNAの調製
Biochem. J. 258, 255-259(1989)に記載されているように、Saccharomyces cereviciae由来乳酸デヒドロゲナーゼ(ScLDH)のアミノ酸配列である591アミノ酸のうち、2~85位のアミノ酸を除去した配列番号1に示す506アミノ酸をコードする配列番号2で示される1521bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、cDNAとして取得した。続いて、Pichia kudriavzevii由来乳酸デヒドロゲナーゼ(PkLDH)のアミノ酸配列である配列番号3で示される578アミノ酸とScLDHを比較し、2~77位を除去した配列番号4で示される502アミノ酸をコードする、配列番号5で示される1509bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、cDNAとして取得した。プラスミドpKK223-3のマルチクローニングサイトに対象遺伝子であるScLDH遺伝子若しくはPkLDH遺伝子を常法により挿入させたDNAコンストラクトを作製した。具体的には、pKK223-3のマルチクローニングサイトにあるIn-Fusion Cloning Siteにて、ScLDH遺伝子若しくはPkLDH遺伝子を、In-Fusion HD Cloning Kit(クロンテック社製)を使用して、キットに添付されたプロトコールに従って連結して、発現用プラスミド(pKK223-3-ScLDH及びpKK223-3-PkLDH)を得た。さらにこれらのプラスミドを用いて大腸菌JM109を形質転換し、大腸菌JM109(pKK223-3-ScLDH)株と大腸菌JM109(pKK223-3-PkLDH)株を、3mlのLB-amp培地[1%(w/v)バクトトリプトン、0.5%(w/v)ペプトン、0.5%(w/v)NaCl、50μg/ml アンピシリン]に接種して、37℃で16時間振とう培養し、それぞれ培養物を得た。
pKK223-3-ScLDHを形質導入した大腸菌BL21(pKK223-3-ScLDH)株を、終濃度0.1mMとなるようにIPTGを添加したLB-amp培地3mlにおいて、25℃で24時間培養した。同様にして、pKK223-3-PkLDHを形質導入した大腸菌BL21(pKK223-3-PkLDH)株を、終濃度0.1mMとなるようにIPTGを添加したLB-amp培地3mlにおいて、37℃で24時間培養した。得られた各培養菌体を10mMのリン酸カリウム緩衝液(pH7.5)で洗浄した後、同緩衝液に懸濁して超音波破砕処理を行い、20,000×gで10分間遠心分離して、ScLDHまたはPkLDHを含む粗酵素液0.6mlを調製した。
上述のScLDHまたはPkLDHを含む粗酵素液を用いて、下記の活性測定法に示した方法により、L-乳酸に対する酸化活性を測定した。本発明のLDHは、L-乳酸を酸化してピルビン酸を生成する反応を触媒する。これを便宜上、LDH活性と呼ぶことがある。
本発明のPkLDHのLDH活性は、この作用原理を利用し、例えば、電子受容体としてフェリシアン化カリウムを用いた以下の測定系を用いて測定することができる。
→ ピルビン酸 + フェロシアン化カリウム
(温度安定性)
終濃度として0.07%BSAを含む100mMリン酸カリウム緩衝液(pH6.0)となるよう上記の粗酵素液を希釈し、温度安定性を調べた。具体的には、実施例1の(2)で調製したLDH酵素液を6U/mlとなるよう希釈し、各温度(35℃、40℃、45℃、50℃、55℃、60℃、65℃)で10分間処理した後、LDH活性を測定し、処理前のLDH活性と比較して残存活性率を測定した。また、比較のため、ScLDHについても同様の試験を行った。結果を図2に示す。
結果から、ScLDHは、45℃で不安定であるが、PkLDHは、55℃熱処理後でも安定であることがわかった。
(酵素の精製)
実施例1の(2)で得られたPkLDHの粗酵素液を20mM リン酸カリウム緩衝液(pH7.5)で平衡化した1mlのQ Sepharose Fast Flow樹脂(GEヘルスケア社製)に供し、樹脂に吸着させた。同緩衝液で樹脂に吸着しないタンパク質を溶出させた。続いて、50mM塩化ナトリウムを含む20mM リン酸カリウム緩衝液(pH7.5)、200mM塩化ナトリウムを含む20mM リン酸カリウム緩衝液(pH7.5)を用いて、洗浄した。次に500mM塩化ナトリウムを含む20mM リン酸カリウム緩衝液(pH7.5)を用いて、吸着したPkLDHを溶出した。得られたPkLDHの粗酵素液を、150mM塩化ナトリウムを含む20mM リン酸カリウム緩衝液(pH7.5)で平衡化したHiLoad 26/10 Q Sepharose HPカラム(GEヘルスケア社製)に供し、1カラム分の体積の緩衝液を流して、目的タンパク質を含む画分を回収した。
さらに回収した酵素液を10mM リン酸カリウム緩衝液(pH7.5)で透析し、同緩衝液で平衡化したHiscreen Capto Qカラム(GEヘルスケア社製)に吸着させ、次に500mM NaCl/10mM リン酸カリウム緩衝液(pH7.5)までグラディエントで徐々にNaCl濃度を高めることで樹脂に吸着していたPkLDHを溶出させ回収した。
得られた画分をSDS-PAGEにより分析し、他の夾雑タンパク質を含まない純度まで精製されていることを確認し、PkLDHの精製標品とした。なお、熱安定性については、粗酵素液と同等であった。
(pH安定性)
実施例3で得られた精製PkLDH酵素液(10U/mL)を用いて、pH安定性を調べた。100mMリン酸カリウム緩衝液(pH6.0-pH7.5)を用い、55℃、15分間の熱処理後、各緩衝液中で酵素を維持し、この各々の酵素を用いる他は実施例1の(3)に記載の活性測定法に従って、活性を測定した。処理後の活性値において最も活性が高かった条件を100%とし、その他の条件における活性値について相対値を求めた。結果を図7に示す。その結果、pH6.5において最も安定であり、次いでpH6.0において92%の相対活性(%)であった。
実施例3で得られた精製PkLDH酵素液(10U/mL)を用いて、至適活性pHを調べた。100mMリン酸カリウム緩衝液(pH6.0-pH7.5)を用い、それぞれのpHにおいて、温度30℃にて酵素反応を行い、相対活性(%)を比較した。結果を図8に示す。その結果、本発明のFMN依存性乳酸デヒドロゲナーゼの至適活性pHは、pH6.5~7.5の範囲で最も高い活性が示された。なお、pH8.0においても良好な活性を維持している可能性はあると考えられる。
実施例3で得られた精製PkLDH酵素液(17U/ml)を用いて、0.2~5mMのL-乳酸を測定した。結果を図9に示す。その結果、乳酸濃度依存的に420nmにおける1分間当たりの吸光度変化量が向上し、L-乳酸を定量できることが示された。
国際公開2015/020200に記載の活性測定方法を参照し、酵素としてPkLDH、基質として終濃度10mMのL-乳酸となるようにし、測定pHを7.5として活性測定を行った。オキシダーゼ活性は、濃度 10mM の基質存在下で1分間 に1μmolの過酸化水素を生成する酵素量を1unit(U)と定義した。用いる酵素量は、デヒドロゲナーゼ活性として600U/mlを示す量とした。その結果、PkLDHのオキシダーゼ活性は検出されなかった。したがって、PkLDHは酸素を電子受容体としない酵素であった。
(印刷電極によるL-乳酸の定量)
実施例3で得られた精製PkLDH酵素液を用いて、印刷電極測定によるL-乳酸の定量を行う。具体的には、カーボンの作用電極、銀の参照電極が印刷されてなる、SCREEN-PRINTED ELECTRODES(DropSens社製、製品番号DRP-110)を、専用コネクター(DropSens社製、DRP-CAC)を用いて、ALS 電気化学アナライザー 814D(BAS社製)に接続し、PkLDH酵素液5μl、1.5Mの塩化カリウムを含有した100mMのリン酸カリウム緩衝液(pH7.5)20μl、フェリシアン化カリウム水溶液25μlを電極上に載せる。そして、+400mV(v.s. Ag/AgCl)の電圧を印加して、所定濃度の乳酸溶液5μLをそれぞれ電極上に載せて反応を行い、120秒後の電流値を測定する。その結果、乳酸を電気化学的測定においても定量できる。
(4)組換え体プラスミドpKK223-3-CaLDH DNA及びpKK223-3-OgLDH DNAの調製と各LDHの生産
Candida inconspicua由来乳酸デヒドロゲナーゼ(CaLDH)のアミノ酸配列である配列番号6で示される571アミノ酸のうち、2~67位を除去した配列番号7で示される505アミノ酸をコードする、配列番号8で示される1518bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、cDNAとして取得した。同様にして、Ogataea parapolymorpha由来乳酸デヒドロゲナーゼ(OgLDH)のアミノ酸配列である配列番号9で示される558アミノ酸のうち、2~56位を除去した配列番号10で示される503アミノ酸をコードする、配列番号11で示される1512bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、cDNAとして取得した。実施例1と同様にして、プラスミドpKK223-3のマルチクローニングサイトに対象遺伝子であるCaLDH遺伝子若しくはOgLDH遺伝子を常法により挿入させたDNAコンストラクトを作製し、発現用プラスミド(pKK223-3-CaLDH及びpKK223-3-OgLDH)を得た。
pKK223-3-CaLDHを形質導入した大腸菌BL21(pKK223-3-CaLDH)株及びpKK223-3-OgLDHを形質導入した大腸菌BL21(pKK223-3-OgLDH)株を、終濃度0.1mMとなるようにIPTGを添加したLB-amp培地3mlにおいて、30℃で24時間培養した。得られた各培養菌体を10mMのリン酸カリウム緩衝液(pH7.5)で洗浄した後、同緩衝液に懸濁して超音波破砕処理を行い、20,000×gで10分間遠心分離して、CaLDHまたはOgLDHを含む粗酵素液0.6mlを調製した。
(温度安定性)
実施例2と同様に、37℃における長期安定性を調べた。ただし、終濃度として0.07%BSAを含む100mMリン酸カリウム緩衝液(pH6.0)、CaLDHまたはOgLDHを約20U/mlとなるよう希釈し、各時間保存した。その後、各時間経過後の残存活性率を測定した。結果を図3(A)に示す。CaLDHは、保存開始から140時間経過後にも72%の活性を保持しており、OgLDHは、保存開始から140時間経過後にも77%の活性を保持しており、ScLDHと比較して非常に安定であった。
PkLDHと同様の手法で、CaLDHとOgLDHの精製を行った。得られた精製酵素液(10U/mL)を用いて、pH安定性を調べた。その結果、CaLDHとOgLDHは共にpH6.5において最も安定であり、pH6.0~7.0の範囲において80%以上の相対活性(%)を示した。
CaLDHとOgLDHのオキシダーゼ活性測定を行ったところ、いずれもオキシダーゼ活性は検出されなかった。したがって、CaLDHとOgLDHは酸素を電子受容体としない酵素であった。
(5)組換え体プラスミドpKK223-3-ThLDH DNAの調製と各LDHの生産
Thermothelomyces thermophilus由来乳酸デヒドロゲナーゼ(ThLDH)のアミノ酸配列である配列番号12で示される499アミノ酸をコードする、配列番号13で示される1500bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、cDNAとして取得した。実施例1と同様にして、プラスミドpKK223-3のマルチクローニングサイトに対象遺伝子であるThLDH遺伝子を常法により挿入させたDNAコンストラクトを作製し、発現用プラスミド(pKK223-3-ThLDH)を得た。
pKK223-3-ThLDHを形質導入した大腸菌BL21(pKK223-3-ThLDH)株を、終濃度1mMとなるようにIPTGを添加したLB-amp培地3mlにおいて、30℃で24時間培養した。得られた各培養菌体を10mMのリン酸カリウム緩衝液(pH7.5)で洗浄した後、同緩衝液に懸濁して超音波破砕処理を行い、20,000×gで10分間遠心分離して、ThLDHを含む粗酵素液0.6mlを調製した。
(温度安定性)
実施例2と同様に、37℃における長期安定性を調べた。終濃度として0.07%BSAを含む100mMリン酸カリウム緩衝液(pH6.0)、ThLDHを約20U/mlとなるよう希釈し、各時間保存した。その後、各時間経過後の残存活性率を測定した。ThLDHは、保存開始から89時間経過後にも74%の活性を保持しており、ScLDHと比較して非常に安定であった。つまり、ThLDHは、37℃にて少なくとも3日間以上経過させた時に、初発活性の70%以上を維持しているといえる。
(6)PkLDH変異体の作製
PkLDHのN末端領域をさらに削除した変異体の構築を行った。まず、配列番号4における2~95位のアミノ酸を欠失させた変異体(PkLDH-96)を作製するために、実施例1で得た組換え体プラスミドpKK223-3-PkLDHを鋳型として、配列番号14、15の合成オリゴヌクレオチド、KOD One PCR Master Mix(東洋紡社製)を用い、以下の条件でPCR反応を行った。すなわち、KOD One PCR Master Mixを10μl、鋳型となるpKK223-3-PkLDHを20ng、上記合成オリゴヌクレオチドをそれぞれ6pmol加えて、滅菌水により全量を20μlとした。調製した反応液を、サーマルサイクラー(Bio-Rad社製)を用いて、「98℃、10秒」-「55℃、5秒」-「68℃、35秒」のサイクルを7回繰り返した。
また、pKK223-3-PkLDHを鋳型として、配列番号28、29の合成オリゴヌクレオチドを用いてPCRを行い、配列番号4記載のアミノ酸配列の161位のフェニルアラニンをロイシンに置換した変異体であるPkLDH/F161LをコードするDNAコンストラクトを得た。
また、pKK223-3-PkLDHを鋳型として、配列番号30、31の合成オリゴヌクレオチドを用いてPCRを行い、配列番号4記載のアミノ酸配列の187位のフェニルアラニンをロイシンに置換した変異体であるPkLDH/F187LをコードするDNAコンストラクトを得た。
また、pKK223-3-PkLDHを鋳型として、配列番号32、33の合成オリゴヌクレオチドを用いてPCRを行い、配列番号4記載のアミノ酸配列の428位のフェニルアラニンをロイシンに置換した変異体であるPkLDH/F428LをコードするDNAコンストラクトを得た。
また、pKK223-3-PkLDH-97を鋳型として、配列番号32、33の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97における配列番号4記載のアミノ酸配列の428位に対応する位置のフェニルアラニンをロイシンに置換した変異体であるPkLDH-97/F428LをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号34、35の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の194位に対応する位置のロイシンをアラニンに置換した変異体であるPkLDH-97/F428L/L194AをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号36、37の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の222位に対応する位置のロイシンをチロシンに置換した変異体であるPkLDH-97/F428L/L222YをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号38、39の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の274位に対応する位置のアラニンをセリンに置換した変異体であるPkLDH-97/F428L/A274SをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号40、41の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の277位に対応する位置のロイシンをセリンに置換した変異体であるPkLDH-97/F428L/L277SをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号42、43の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の313位に対応する位置のフェニルアラニンをアラニンに置換した変異体であるPkLDH-97/F428L/F313AをコードするDNAコンストラクトを得た。
また、PkLDH-97/F428Lを鋳型として、配列番号44、45の合成オリゴヌクレオチドを用いてPCRを行い、PkLDH-97/F428Lにおける配列番号4記載のアミノ酸配列の314位に対応する位置のイソロイシンをセリンに置換した変異体であるPkLDH-97/F428L/I314SをコードするDNAコンストラクトを得た。
また、PkLDH-97をコードするDNAコンストラクトを作製した時と同様に、配列番号4における2位のアミノ酸を欠失させた変異体(PkLDH-3/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、54の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-3/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~3位のアミノ酸を欠失させた変異体(PkLDH-4/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、55の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-4/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~4位のアミノ酸を欠失させた変異体(PkLDH-5/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、56の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-4/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~5位のアミノ酸を欠失させた変異体(PkLDH-6/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、57の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-6/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~6位のアミノ酸を欠失させた変異体(PkLDH-7/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、58の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-7/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~7位のアミノ酸を欠失させた変異体(PkLDH-8/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、59の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-8/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~8位のアミノ酸を欠失させた変異体(PkLDH-9/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、60の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-9/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~9位のアミノ酸を欠失させた変異体(PkLDH-10/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、61の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-10/F428LをコードするDNAコンストラクトを得た。
また、配列番号4における2~10位のアミノ酸を欠失させた変異体(PkLDH-11/F428L)を作製するために、PkLDH/F428Lを鋳型として、配列番号14、62の合成オリゴヌクレオチドを用いてPCRを行い、その結果、PkLDH-11/F428LをコードするDNAコンストラクトを得た。
(温度安定性)
終濃度として0.15%BSAを含む150mMリン酸カリウム緩衝液(pH7.5)となるよう実施例10で作製した粗酵素液(PkLDH-96~PkLDH-104)を希釈し、温度安定性を調べた。具体的には、実施例10で調製したN末端削除変異体であるLDH酵素液を6U/mlとなるよう希釈し、55℃で15分間処理した後、LDH活性を測定し、処理前のLDH活性と比較して残存活性率を測定した。また、比較のため、PkLDHについても同様の試験を行った。結果を図12に示す。PkLDH-96~PkLDH-104はいずれもPkLDHよりも残存活性率が高く、熱安定性が高いことが分かった。また、その他のN末端削除変異体(PkLDH-76、PkLDH-84、PkLDH-92、PkLDH-110、PkLDH-3/F428L、PkLDH-4/F428L、PkLDH-5/F428L、PkLDH-6/F428L、PkLDH-7/F428L、PkLDH-8/F428L、PkLDH-9/F428L、PkLDH-10/F428L、PkLDH-11/F428L)について、同様にして50℃で15分間処理した。続いて、LDH活性測定用試薬として、終濃度0.09mMの2,6-ジクロロインドフェノール(DCIP)、終濃度0.5mMのフェナジンメトサルフェート(PMS)、終濃度10mMのL-乳酸及び終濃度100mMのリン酸カリウム緩衝液(pH7.5)を準備した。96穴プレート中に、熱処理後の酵素液を5μL、LDH活性測定用試薬を145μL添加し、37℃で5分間、インキュベートしたところ、明らかに活性測定試薬の色が黄色へと変化した。したがって、50℃の熱処理で完全に失活するScLDHと比較して、これらの変異体は安定性が高いことが分かった。
続いて、終濃度として0.15%BSAを含む150mMリン酸カリウム緩衝液(pH7.5)となるよう実施例10で作製した粗酵素液(PkLDH/F161L、PkLDH/F187L、PkLDH/F428L)を希釈し、温度安定性を調べた。具体的には、実施例10で調製した一置換変異LDH酵素液を6U/mlとなるよう希釈し、55℃で15分間処理した後、LDH活性を測定し、処理前のLDH活性と比較して残存活性率を測定した。また、比較のため、PkLDHについても同様の試験を行った。結果を図13に示す。PkLDH/F161L、PkLDH/F187L、PkLDH/F428LはいずれもPkLDHよりも残存活性率が高く、熱安定性が高いことが分かった。
また、実施例10で作製した粗酵素液(PkLDH-97/F428L/L194A、PkLDH-97/F428L/L222Y、PkLDH-97/F428L/A274S、PkLDH-97/F428L/L277S、PkLDH-97/F428L/F313A、PkLDH-97/F428L/I314S)を用いて、50℃で15分間処理した。続いて、LDH活性測定用試薬として、上記のDCIP及びPMSによる系を用い、熱処理後の酵素液を5μL、LDH活性測定用試薬を145μL添加し、37℃で5分間、インキュベートしたところ、明らかに活性測定試薬の色が黄色へと変化した。したがって、50℃の熱処理で完全に失活するScLDHと比較して、これらの変異体は安定性が高いことが分かった。なお、PMSの代わりに、1-メトキシフェナジンメトサルフェートを用いて同様に活性測定を行っても同様の結果であった。
(PkLDH固定化電極によるL-乳酸の定量)
実施例3で得られた精製PkLDH酵素液を固定化した電極を用いてL-乳酸の定量を行った。具体的には、カーボンの作用電極が印刷されてなる、SCREEN-PRINTED ELECTRODES(DropSens社製、製品番号DRP-C110)の作用電極上に12U分のPkLDHを塗布・乾燥させた。続いて、2%のポリ(エチレングリコール)ジグリシジルエーテル(Mn:6000、シグマ社製)を3μL塗布し、4℃にて22時間反応させた。超純水で洗浄し、PkLDH固定化電極とした。専用コネクター(DropSens社製、DRP-CAC)を用いて、ALS 電気化学アナライザー 814D(BAS社製)に接続し、さらに銀塩化銀参照電極と白金電極と接続し、0.1mg/mlのBindschedler‘s Green Leuco Base(東京化成社製)を含有したPBS(pH7.4)10ml中に3つの電極を浸漬させた。+200mV(vs Ag/AgCl)を印加し、一定時間ごとにL-乳酸溶液を添加した際の応答電流値を記録した。その結果を図8に示す。1~7mMのL-乳酸を添加した際に、乳酸濃度依存的に応答電流が増加することが示され、L-乳酸を定量できた。
3 対極
5 参照極
7 配線部
9 端子
10 センサチップ
11 基盤
13 スペーサ
15 カバー
19 反応層
100 測定部
101 制御部
102 温度センサ
103 記憶部
104 通信部
105 電池
106 測定装置
Claims (16)
- 検体の状態を評価するためのデバイスであって、
検体に乳酸デヒドロゲナーゼを作用させるための作用部と、
乳酸デヒドロゲナーゼを作用させた検体の状態を感知するためのセンサであって、作用部での検体の状態を感知することが可能なように配置されるセンサと
を含む、デバイス。 - センサからの信号を出力するための出力部をさらに含む、請求項1記載のデバイス。
- 請求項2記載のデバイスと、
デバイスの出力部に接続され、センサからの信号を処理するためのデータ処理ユニットと
を含む、システム。 - 検体の状態を、デバイス及びデータ処理ユニットを含むシステムによって評価するためのプログラムであって、
デバイスが、
検体に乳酸デヒドロゲナーゼを作用させるための作用部と、
乳酸デヒドロゲナーゼを作用させた検体の状態を感知するためのセンサであって、作用部での検体の状態を感知することが可能なように配置されるセンサと、
センサからの信号を出力するための出力部と
を含み、
データ処理ユニットが、デバイスの出力部に接続され、センサからの信号を処理するように構成され、
プログラムが、デバイスに対して、
センサにより、乳酸デヒドロゲナーゼを作用部において作用させた検体の状態を感知して測定し、信号に変換するための、測定処理と、
前記測定処理で得られた信号を出力部からデータ処理ユニットに対して転送するための、転送処理と、
を実行させ、
プログラムが、前記データ処理ユニットに対して、前記測定処理で得られた信号に対して所定の処理をするための、データ処理を実行させる、プログラム。 - 請求項1又は2記載のデバイス、または請求項3記載のシステムを用いる、検体の状態を評価する方法。
- 検体が、ヒトおよび非ヒト生物の体液、間質液、血液、尿、涙、汗、唾液、皮膚、肉、眼球、角膜、胃液、飲食品、醸造物、化成品、水、土壌を含む乳酸含有組成物である、請求項5記載の方法。
- 検体の状態が、運動負荷に対する身体状態、疾病状態、乳酸量の変化を伴う醸造物の醸造状態、乳酸量の変化を伴う飲食品の熟成・追熟度合、乳酸量の変化を伴う化成品製造の乳酸含有割合、乳酸量の変化を伴う水、土壌中の乳酸量である、請求項5又は6記載の方法。
- 検体の状態をモニタリングするためのデバイスであって、デバイスは、検体に、
(A)溶液中で、37℃にて10日間経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ、
(B)溶液中で、37℃にて3日間以上経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ、又は
(C)溶液中で、37℃にて15時間以上経過させた時に、初発活性の約20%以上を維持しているフラビン依存性乳酸デヒドロゲナーゼ
を作用させるための作用部を含む、デバイス。 - 請求項8記載のデバイスがさらに出力部を含み、その出力部がデータ処理ユニットに接続される、システム。
- 請求項8記載のデバイスまたは請求項9記載のシステムを用いる、検体の状態をモニタリングする方法。
- 配列番号4で示されるアミノ酸配列における110~502位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、配列番号7で示されるアミノ酸配列における113~505位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、アミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、配列番号10で示されるアミノ酸配列における112~503位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列、又は配列番号12で示されるアミノ酸配列における102~499位のアミノ酸配列又はそれと70%以上の同一性を有するアミノ酸配列を含む、乳酸デヒドロゲナーゼ。
- 配列番号4、配列番号7、配列番号10、又は配列番号12に示されるアミノ酸配列又はそれとの同一性が70%以上のアミノ酸配列を有する、請求項11記載の乳酸デヒドロゲナーゼ。
- 請求項11又は12記載の乳酸デヒドロゲナーゼをコードする核酸。
- 請求項13記載の核酸を有する、宿主細胞。
- 請求項14記載の宿主細胞を培養することを含む、乳酸デヒドロゲナーゼの製造方法。
- 検体の状態を評価するための方法であって、
i)請求項11又は12記載の乳酸デヒドロゲナーゼと検体を接触させる工程、及び
ii)乳酸を測定する工程
を含む、方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21756429.3A EP4108678A4 (en) | 2020-02-21 | 2021-02-18 | DEVICE FOR EVALUATION OF THE CONDITION OF A SAMPLE, SYSTEM COMPRISING SAME, METHOD FOR EVALUATION OF THE CONDITION OF A SAMPLE AND LACTATE DEHYDROGENASE USED FOR THIS PURPOSE |
KR1020227032145A KR20220143091A (ko) | 2020-02-21 | 2021-02-18 | 검체의 상태를 평가하기 위한 디바이스, 그것을 포함하는 시스템, 검체의 상태를 평가하는 방법 및 그에 사용되는 유산 데히드로게나아제 |
JP2022501977A JPWO2021167011A1 (ja) | 2020-02-21 | 2021-02-18 | |
US17/801,033 US20230213499A1 (en) | 2020-02-21 | 2021-02-18 | Device for evaluating state of sample, system containing same, method for evaluating state of sample and lactate dehydrogenase used therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020028722 | 2020-02-21 | ||
JP2020-028722 | 2020-02-21 | ||
JP2020-106467 | 2020-06-19 | ||
JP2020106467 | 2020-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021167011A1 true WO2021167011A1 (ja) | 2021-08-26 |
Family
ID=77392166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/006153 WO2021167011A1 (ja) | 2020-02-21 | 2021-02-18 | 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230213499A1 (ja) |
EP (1) | EP4108678A4 (ja) |
JP (1) | JPWO2021167011A1 (ja) |
KR (1) | KR20220143091A (ja) |
WO (1) | WO2021167011A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071417A1 (ja) * | 2020-09-29 | 2022-04-07 | キッコーマン株式会社 | フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 |
WO2022258733A1 (en) | 2021-06-09 | 2022-12-15 | Directsens Gmbh | Novel production method of flavocytochrome b2 |
WO2023013498A1 (ja) * | 2021-08-03 | 2023-02-09 | キッコーマン株式会社 | 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法 |
TWI814233B (zh) * | 2022-01-28 | 2023-09-01 | 住華科技股份有限公司 | 硼酸檢測試片及硼酸檢測方法 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58175498A (ja) * | 1982-03-26 | 1983-10-14 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 液体中の物質の測定用試験系および試験方法 |
JPS61159164A (ja) * | 1984-09-21 | 1986-07-18 | ジヨナサン・エル・キ−ル | ミクロ化学発光アツセイシステム |
JPH04346796A (ja) * | 1991-05-21 | 1992-12-02 | Asahi Chem Ind Co Ltd | 乳酸またはピルビン酸の高感度定量法および定量用組成物 |
JPH06153995A (ja) * | 1992-11-26 | 1994-06-03 | Sekisui Chem Co Ltd | 細菌ホロルシフェラーゼを用いた測定法 |
JPH08327581A (ja) * | 1995-05-24 | 1996-12-13 | Co Ri Al S C P A | 栄養的に注目される有機物質中の乳酸の測定方法およびこの方法を実施するためのバイオセンサー |
JPH10513063A (ja) * | 1995-11-22 | 1998-12-15 | ベーリンガー マンハイム ゲーエムベーハー | 安定化された補酵素溶液、並びにアルカリ性環境下でのデヒドロゲナーゼ及び基質の測定のためのその使用 |
JP2009517045A (ja) * | 2005-11-23 | 2009-04-30 | ネイチャーワークス・エル・エル・シー | L−又はd−ラクタート:フェリチトクロームc酸化還元酵素遺伝子が機能しない乳酸産生酵母 |
WO2012068236A2 (en) * | 2010-11-16 | 2012-05-24 | Dyadic International (Usa) Inc. | Novel fungal oxidoreductases |
JP2014501502A (ja) * | 2010-11-22 | 2014-01-23 | キンバリー クラーク ワールドワイド インコーポレイテッド | 良好な健康状態のバイオマーカを検出するための膣用インジケータ |
JP5593689B2 (ja) | 2009-12-09 | 2014-09-24 | 東洋紡株式会社 | 乳酸オキシダーゼ組成物 |
WO2015017721A1 (en) * | 2013-07-31 | 2015-02-05 | Novozymes A/S | 3-hydroxypropionic acid production by recombinant yeasts expressing an insect aspartate 1-decarboxylase |
WO2015020200A1 (ja) | 2013-08-09 | 2015-02-12 | キッコーマン株式会社 | 改変型アマドリアーゼ及びその製造法、並びにアマドリアーゼの界面活性剤耐性向上剤及びこれを用いたHbA1c測定用組成物 |
JP2017100039A (ja) | 2015-12-01 | 2017-06-08 | パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカPanasonic Intellectual Property Corporation of America | 体調推定装置、体調推定システム及びプロセッサ |
WO2017163521A1 (ja) | 2016-03-23 | 2017-09-28 | 日本電気株式会社 | 情報処理装置、その制御方法ならびにその制御プログラム |
JP2018519507A (ja) | 2015-06-15 | 2018-07-19 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 安定した乳酸応答性の酵素、電極およびセンサ並びにそれらの製造方法および使用方法 |
JP2019150649A (ja) | 2017-11-28 | 2019-09-12 | 株式会社ユピテル | 電子機器およびプログラム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10358664B2 (en) * | 2015-02-27 | 2019-07-23 | Novozymes A/S | Mutant host cells for the production of 3-hydroxypropionic acid |
CA3036837A1 (en) * | 2016-09-16 | 2018-03-22 | Cargill, Incorporated | Genetically modified lactate-consuming yeasts and fermentation processes using such genetically modified yeasts |
WO2022071417A1 (ja) * | 2020-09-29 | 2022-04-07 | キッコーマン株式会社 | フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 |
-
2021
- 2021-02-18 EP EP21756429.3A patent/EP4108678A4/en active Pending
- 2021-02-18 KR KR1020227032145A patent/KR20220143091A/ko unknown
- 2021-02-18 JP JP2022501977A patent/JPWO2021167011A1/ja active Pending
- 2021-02-18 WO PCT/JP2021/006153 patent/WO2021167011A1/ja unknown
- 2021-02-18 US US17/801,033 patent/US20230213499A1/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58175498A (ja) * | 1982-03-26 | 1983-10-14 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 液体中の物質の測定用試験系および試験方法 |
JPS61159164A (ja) * | 1984-09-21 | 1986-07-18 | ジヨナサン・エル・キ−ル | ミクロ化学発光アツセイシステム |
JPH04346796A (ja) * | 1991-05-21 | 1992-12-02 | Asahi Chem Ind Co Ltd | 乳酸またはピルビン酸の高感度定量法および定量用組成物 |
JPH06153995A (ja) * | 1992-11-26 | 1994-06-03 | Sekisui Chem Co Ltd | 細菌ホロルシフェラーゼを用いた測定法 |
JPH08327581A (ja) * | 1995-05-24 | 1996-12-13 | Co Ri Al S C P A | 栄養的に注目される有機物質中の乳酸の測定方法およびこの方法を実施するためのバイオセンサー |
JPH10513063A (ja) * | 1995-11-22 | 1998-12-15 | ベーリンガー マンハイム ゲーエムベーハー | 安定化された補酵素溶液、並びにアルカリ性環境下でのデヒドロゲナーゼ及び基質の測定のためのその使用 |
JP2009517045A (ja) * | 2005-11-23 | 2009-04-30 | ネイチャーワークス・エル・エル・シー | L−又はd−ラクタート:フェリチトクロームc酸化還元酵素遺伝子が機能しない乳酸産生酵母 |
JP5593689B2 (ja) | 2009-12-09 | 2014-09-24 | 東洋紡株式会社 | 乳酸オキシダーゼ組成物 |
WO2012068236A2 (en) * | 2010-11-16 | 2012-05-24 | Dyadic International (Usa) Inc. | Novel fungal oxidoreductases |
JP2014501502A (ja) * | 2010-11-22 | 2014-01-23 | キンバリー クラーク ワールドワイド インコーポレイテッド | 良好な健康状態のバイオマーカを検出するための膣用インジケータ |
WO2015017721A1 (en) * | 2013-07-31 | 2015-02-05 | Novozymes A/S | 3-hydroxypropionic acid production by recombinant yeasts expressing an insect aspartate 1-decarboxylase |
WO2015020200A1 (ja) | 2013-08-09 | 2015-02-12 | キッコーマン株式会社 | 改変型アマドリアーゼ及びその製造法、並びにアマドリアーゼの界面活性剤耐性向上剤及びこれを用いたHbA1c測定用組成物 |
JP2018519507A (ja) | 2015-06-15 | 2018-07-19 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 安定した乳酸応答性の酵素、電極およびセンサ並びにそれらの製造方法および使用方法 |
JP2017100039A (ja) | 2015-12-01 | 2017-06-08 | パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカPanasonic Intellectual Property Corporation of America | 体調推定装置、体調推定システム及びプロセッサ |
WO2017163521A1 (ja) | 2016-03-23 | 2017-09-28 | 日本電気株式会社 | 情報処理装置、その制御方法ならびにその制御プログラム |
JP2019150649A (ja) | 2017-11-28 | 2019-09-12 | 株式会社ユピテル | 電子機器およびプログラム |
Non-Patent Citations (7)
Title |
---|
"Bulletin of Tokai University, Faculty of Oceanography", vol. 4, 2006, article "Sea-Nature and Culture", pages: 31 - 46 |
"The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016", PNAS, vol. 112, no. 37, 15 September 2015 (2015-09-15), pages 11642 - 11647 |
BIOCHEM. J., vol. 258, 1989, pages 255 - 259 |
DATABASE UNIPROTKB 31 July 2019 (2019-07-31), ANONYMOUS GENE: "UniProtKB - A0A4T0X365 (A0A4T0X365_9ASCO)", XP055850100, retrieved from UNIPROT Database accession no. A0A4T0X365 * |
METHODS ENZYMOL, vol. 53, 1978, pages 238 - 56 |
RESEARCH JOURNAL OF SPORTS PERFORMANCE, vol. 3, 2011, pages 31 - 48 |
See also references of EP4108678A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071417A1 (ja) * | 2020-09-29 | 2022-04-07 | キッコーマン株式会社 | フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 |
WO2022258733A1 (en) | 2021-06-09 | 2022-12-15 | Directsens Gmbh | Novel production method of flavocytochrome b2 |
WO2023013498A1 (ja) * | 2021-08-03 | 2023-02-09 | キッコーマン株式会社 | 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法 |
TWI814233B (zh) * | 2022-01-28 | 2023-09-01 | 住華科技股份有限公司 | 硼酸檢測試片及硼酸檢測方法 |
Also Published As
Publication number | Publication date |
---|---|
US20230213499A1 (en) | 2023-07-06 |
KR20220143091A (ko) | 2022-10-24 |
EP4108678A1 (en) | 2022-12-28 |
EP4108678A4 (en) | 2024-03-27 |
JPWO2021167011A1 (ja) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021167011A1 (ja) | 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ | |
JP4359595B2 (ja) | グルコースセンサおよびグルコース濃度測定装置 | |
Mandpe et al. | Glucose oxidase-based biosensor for glucose detection from biological fluids | |
TWI485249B (zh) | Modified glucose dehydrogenase | |
JP6184326B2 (ja) | 基質特異性が向上したフラビン結合型グルコースデヒドロゲナーゼ | |
US20130240374A1 (en) | Glucose Dehydrogenase/Cytochrome Fusion Protein | |
Hiraka et al. | Minimizing the effects of oxygen interference on L-lactate sensors by a single amino acid mutation in Aerococcus viridans L-lactate oxidase | |
US8247189B2 (en) | Modified flavin adenine dinucleotide-dependent glucose dehydrogenase | |
Zhang et al. | A wearable biosensor based on bienzyme gel-membrane for sweat lactate monitoring by mounting on eyeglasses | |
CN101421396A (zh) | 吡咯并喹啉醌依赖性可溶性葡萄糖脱氢酶的改良突变体 | |
JPWO2015099112A1 (ja) | 熱安定性が向上したフラビン結合型グルコースデヒドロゲナーゼ | |
JP7084867B2 (ja) | フラビン結合型グルコースデヒドロゲナーゼ改変体 | |
JP2015084676A (ja) | 耐熱性に優れたフラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ | |
CN108473966A (zh) | 来自类球红细菌的突变体3-羟基丁酸脱氢酶及其相关方法和用途 | |
CN108350439A (zh) | 来自粪产碱菌的突变体3-羟基丁酸脱氢酶及其相关方法和用途 | |
JP6133029B2 (ja) | 安定性が高められた変異型乳酸オキシダーゼ、ならびにそれに関連する生成物、方法および使用 | |
JP6635913B2 (ja) | 比活性が向上したフラビン結合型グルコースデヒドロゲナーゼ | |
JP6101011B2 (ja) | フラビン結合型グルコースデヒドロゲナーゼを含む組成物の安定性を向上する方法 | |
Sacchi et al. | Biosensors for D-amino acid detection | |
JP6934720B2 (ja) | 基質特異性が向上したフラビン結合型グルコースデヒドロゲナーゼ | |
Tarasov et al. | Nano-and microelectrochemical biosensors for determining blood glucose | |
JP6652756B2 (ja) | フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有する変異型タンパク質 | |
JP7165493B2 (ja) | 保存安定性に優れたグルコースデヒドロゲナーゼ及び持続血糖測定 | |
JP2011217731A (ja) | 改変型フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ | |
JP5793835B2 (ja) | フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼを用いるグルコース測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21756429 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022501977 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227032145 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021756429 Country of ref document: EP Effective date: 20220921 |